<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003754.pub2" GROUP_ID="INFECTN" ID="360602012716003513" MERGED_FROM="" MODIFIED="2011-11-09 22:03:08 +0000" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="CMUR" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.8">
<COVER_SHEET MODIFIED="2011-11-09 21:58:11 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE MODIFIED="2011-11-01 14:48:08 +0000" MODIFIED_BY="[Empty name]">Oral rehydration salt solution for treating cholera: &#8804; 270 mOsm/L solutions vs &#8805; 310 mOsm/L solutions</TITLE>
<CONTACT>
<PERSON ID="8B0BF7C782E26AA20026894812FC1FDD" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Alfred</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Musekiwa</LAST_NAME>
<SUFFIX/>
<POSITION>Biostatistician</POSITION>
<EMAIL_1>alfred.musekiwa@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>072 503 7613</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Wits Reproductive Health &amp; HIV Institute (WRHI), Faculty of Health Sciences</DEPARTMENT>
<ORGANISATION>University of the Witwatersrand</ORGANISATION>
<ADDRESS_1>PO Box 18512</ADDRESS_1>
<ADDRESS_2>Hillbrow</ADDRESS_2>
<CITY>Johannesburg</CITY>
<ZIP>2038</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 11 358 5338</PHONE_1>
<PHONE_2/>
<FAX_1>+27 11 358 5400</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-11-09 21:58:11 +0000" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="8B0BF7C782E26AA20026894812FC1FDD" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Alfred</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Musekiwa</LAST_NAME>
<SUFFIX/>
<POSITION>Biostatistician</POSITION>
<EMAIL_1>alfred.musekiwa@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>072 503 7613</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Wits Reproductive Health &amp; HIV Institute (WRHI), Faculty of Health Sciences</DEPARTMENT>
<ORGANISATION>University of the Witwatersrand</ORGANISATION>
<ADDRESS_1>PO Box 18512</ADDRESS_1>
<ADDRESS_2>Hillbrow</ADDRESS_2>
<CITY>Johannesburg</CITY>
<ZIP>2038</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 11 358 5338</PHONE_1>
<PHONE_2/>
<FAX_1>+27 11 358 5400</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6985" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jimmy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Volmink</LAST_NAME>
<SUFFIX/>
<POSITION>Dean</POSITION>
<EMAIL_1>jvolmink@sun.ac.za</EMAIL_1>
<EMAIL_2/>
<URL>www.sun.ac.za</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1>PO Box 19063</ADDRESS_1>
<ADDRESS_2/>
<CITY>Tygerberg</CITY>
<ZIP>7505</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 938 9643</PHONE_1>
<PHONE_2/>
<FAX_1>+27 21 938 9558</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-11-08 09:27:27 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="9" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="4" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2011-11-08 10:24:16 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-11-08 10:24:16 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>The review has a new author team and has some data errors corrected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-08 10:21:31 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Title changed to 'Oral rehydration salt solution for treating cholera: &#8804; 270 mOsm/L solutions vs &#8805; 310 mOsm/L solutions'. Changes to secondary outcomes measures, detailed in section 'Differences between protocol and review'. Several apparent errors in data extraction from previous version were corrected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-11-08 09:30:57 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-08 09:30:57 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Corrected stool volume SMD for Alam 2000, as pointed out in Peter Gotzsche's query (Sept 2006)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-08 09:30:04 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-11-08 10:48:27 +0000" MODIFIED_BY="Alfred Musekiwa">
<INTERNAL_SOURCES MODIFIED="2011-11-08 10:48:27 +0000" MODIFIED_BY="Alfred Musekiwa">
<SOURCE MODIFIED="2011-11-08 10:48:13 +0000" MODIFIED_BY="Alfred Musekiwa">
<NAME>South African Medical Research Council</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2011-11-08 10:48:19 +0000" MODIFIED_BY="Alfred Musekiwa">
<NAME>Stellenbosch University</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-11-08 10:48:27 +0000" MODIFIED_BY="[Empty name]">
<NAME>Wits Reproductive Health and HIV Institute (WRHI)</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-09 22:01:27 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-11-08 12:08:54 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-11-08 12:06:32 +0000" MODIFIED_BY="[Empty name]">Oral rehydration salt solutions for treating cholera: lower salt content versus higher salt content solutions</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-08 12:08:54 +0000" MODIFIED_BY="[Empty name]">
<P>Cholera is caused by pathogenic bacteria ingested with contaminated food or water and is commonly found where sanitation measures are poor. It causes severe diarrhoea and vomiting, which can lead to profound dehydration and potentially death. Oral rehydration solution (ORS) is an effective treatment for diarrhoea, and ORS with a salt concentration of &#8804; 270 mOsm/L, which has a lower electrolyte content than the earlier ORS &#8805; 310 mOsm/L, is safe and more effective in people with non-cholera diarrhoea. This review found that ORS &#8804; 270 mOsm/L appears to be as effective as ORS &#8805; 310 mOsm/L at rehydrating people with cholera, but may lead to low blood salt levels. More research is needed to better understand these potential safety issues.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-08 10:25:57 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-11-08 10:24:57 +0000" MODIFIED_BY="[Empty name]">
<P>Oral rehydration solution (ORS) is used to treat the dehydration caused by diarrhoeal diseases, including cholera. ORS formulations with an osmolarity (a measure of solute concentration) of &#8804; 270 mOsm/L (ORS &#8804; 270) are safe and more effective than ORS formulations with an osmolarity of &#8805; 310 mOsm/L (ORS &#8805; 310) for treating non-cholera diarrhoea. As cholera causes rapid electrolyte loss, it is important to know if these benefits are similar for people suffering from cholera.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-11-08 10:25:06 +0000" MODIFIED_BY="[Empty name]">
<P>To compare the safety and efficacy of ORS &#8804;270 with ORS &#8805; 310 for treating dehydration due to cholera.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-05-18 17:02:09 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Disease Group Specialized Register (April 2011), CENTRAL (<I>The Cochrane Library</I> Issue 4, 2011), MEDLINE (1966 to April 2011), EMBASE (1974 to April 2011), and LILACS (1982 to April 2011). We also contacted organizations and searched reference lists.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-08 10:25:13 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials comparing ORS &#8804; 270 with ORS &#8805; 310 for treating adults and children with acute diarrhoea due to cholera.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-08 10:25:19 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Two reviewers independently applied eligibility criteria, assessed trial quality, and extracted data. We pooled dichotomous data using risk ratio (RR), pooled continuous data using mean difference (MD) or the standardized mean difference (SMD), and presented the results with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-08 10:25:49 +0000" MODIFIED_BY="[Empty name]">
<P>For glucose-based ORS, seven trials (718 participants) met the inclusion criteria. Biochemical hyponatraemia (blood sodium levels &lt; 130 mmol/L) was more common with ORS &#8804; 270 (RR 1.67, CI 1.09 to 2.57; 465 participants, four trials), while a higher level of severe biochemical hyponatraemia (blood sodium levels &lt; 125 mmol/L) in the same group was not significant (RR 1.58, CI 0.62 to 4.04; 465 participants, four trials). No instances of symptomatic hyponatraemia or death were noted in the trials that intended to record them. We found no statistically significant difference in the need for unscheduled intravenous infusion. Analyses separating children and adults showed no obvious trends.</P>
<P>Two trials also examined rice-based ORS. In the ORS &#8804; 270 group, duration of diarrhoea was shorter (MD -11.42 hours, CI -13.80 to -9.04; 102 participants, two trials).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-08 10:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>In people with cholera, ORS &#8804; 270 is associated with biochemical hyponatraemia when compared with ORS &#8805; 310, but there are no differences in terms of other outcomes. Although this risk does not appear to be associated with any serious consequences, the total patient experience in existing trials is small. Under wider practice conditions, especially where patient monitoring is difficult, caution is warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-09 22:01:00 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-11-08 10:29:04 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-11-08 10:27:25 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Cholera is one of the most serious types of infectious diarrhoeal disease, inflicting severe social and economic hardship in outbreak areas (<LINK REF="REF-WHO-2001a" TYPE="REFERENCE">WHO 2001a</LINK>). In 2007, the World Health Organization (WHO) noted an increase in the number of reported cholera cases and deaths, with an estimated 177,963 cases resulting in 4031 deaths across 53 countries, representing a 46% increase on the mean number of cases reported between 2002 and 2005 (<LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>). Due to under-reporting (in light of travel and trade-related sanction concerns) and other surveillance system limitations, reported cases are thought to represent only a fraction of actual cases (<LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>). Caused by ingesting food or water containing the bacterium <I>Vibrio cholerae</I>, cholera can spread rapidly among populations lacking access to safe water and adequate sanitation facilities. Upon infecting the small intestine, the bacteria produce a protein enterotoxin that induces the hypersecretion of water and electrolytes by the small intestinal mucosa. Symptoms of cholera include acute watery diarrhoea, vomiting, and severe dehydration, which can lead to death within 24 hours if left untreated (<LINK REF="REF-Sack-2004" TYPE="REFERENCE">Sack 2004</LINK>).<BR/>
</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-11-08 10:28:16 +0000" MODIFIED_BY="[Empty name]">
<P>Oral rehydration solution (ORS) was developed in the late 1960s. It is an important intervention for reducing the morbidity and mortality associated with diarrhoeal disease, regardless of etiology (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). ORS has been highly effective in reducing the high mortality rates experienced during cholera outbreaks, which often reached 50 per cent before the introduction of this treatment (<LINK REF="REF-Quotah-1999" TYPE="REFERENCE">Quotah 1999</LINK>). Utilizing a simple and inexpensive solution of sodium and glucose, ORS enhances the absorption of sodium and fluid in the small intestine, even in cases of enterotoxic diarrhoea, where fluid loss is often substantial.</P>
<P>The former standard formulation of ORS consisted of 90 mmol/L of sodium, 20 mmol/L of potassium, 80 mmol/L of chloride, 10 mmol/L of citrate, and 111 mmol/L of glucose, with a total osmolarity of 311 mmol/L (ORS &#8805; 310). Initially intended to replace sodium losses in adults with cholera, this formulation was previously recommended by the WHO and the United Nations Children's Fund (UNICEF) for treating all types of diarrhoea in children and adults (<LINK REF="REF-Rabbani-2000" TYPE="REFERENCE">Rabbani 2000</LINK>; <LINK REF="REF-WHO-2001b" TYPE="REFERENCE">WHO 2001b</LINK>; <LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Even though the expanded use of this solution has saved millions of lives, its optimal composition remains an issue of debate (<LINK REF="REF-Duggan-2004" TYPE="REFERENCE">Duggan 2004</LINK>; <LINK REF="REF-Guarino-2000" TYPE="REFERENCE">Guarino 2000</LINK>; <LINK REF="REF-Nalin-2004" TYPE="REFERENCE">Nalin 2004</LINK>).</P>
<P>In 2001, a Cochrane review changed the worldwide ORS formula for treating diarrhoea of all causes, reducing the total osmolarity to 245 mmol/L (ORS &#8804; 270; <LINK REF="REF-Hahn-2002" TYPE="REFERENCE">Hahn 2002</LINK>); this is currently regarded as the standard global formula.</P>
</INTERVENTION>
<THEORY MODIFIED="2011-11-08 10:28:21 +0000" MODIFIED_BY="[Empty name]">
<P>Potential problems with the ORS &#8805; 310 formulation are that it may not lower stool output or duration of diarrhoea, which reduces its acceptance in many communities (<LINK REF="REF-Rabbani-2000" TYPE="REFERENCE">Rabbani 2000</LINK>). Alternative formulations, including those that use lower electrolyte concentrations or replace glucose with complex carbohydrates such as rice powder, or both, have been introduced with the aim of reducing osmolarity in order to promote greater salt and water absorption in the small intestine.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-11-08 10:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>ORS &#8804; 270 was found to be just as safe and more effective than ORS &#8805; 310 for treating diarrhoea in children (<LINK REF="REF-Hahn-2002" TYPE="REFERENCE">Hahn 2002</LINK>). Acknowledging the benefits of ORS &#8804; 270 solutions, including reduced stool output and duration of diarrhoea, WHO and UNICEF now recommend that countries use and manufacture formulations with a total osmolarity of 245 mmol/L (<LINK REF="REF-WHO-2001b" TYPE="REFERENCE">WHO 2001b</LINK>). However, there are concerns about potential adverse effects of using ORS &#8804; 270 solutions to treat people with cholera (<LINK REF="REF-Hahn-2002" TYPE="REFERENCE">Hahn 2002</LINK>; <LINK REF="REF-Nalin-2004" TYPE="REFERENCE">Nalin 2004</LINK>; <LINK REF="REF-WHO-2001b" TYPE="REFERENCE">WHO 2001b</LINK>). Because cholera is associated with significant electrolyte loss, especially among children, the use of ORS with reduced sodium levels may place patients at a greater risk of developing biochemical hyponatraemia (blood sodium levels &lt; 130 mmol/L) (<LINK REF="REF-Fuchs-2001" TYPE="REFERENCE">Fuchs 2001</LINK>). This can result in severe illness, including seizures, respiratory arrest, coma (symptomatic hyponatraemia), and even death. Especially in areas where cholera is endemic, practitioners require the best available evidence about the balance between the benefits and risks of different ORS formulations.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-08 10:29:10 +0000" MODIFIED_BY="[Empty name]">
<P>To compare the safety and efficacy of ORS &#8804; 270 and ORS &#8805; 310 for treating dehydration due to cholera.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-09 16:48:54 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-09 16:47:49 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-11-08 10:29:18 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children with acute diarrhoea caused by <I>V. cholerae</I>, either confirmed (by stool microscopy or stool culture) or presumed.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-11-09 16:47:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>ORS formulations with an osmolarity of &#8804; 270 mOsm/L (total osmolarity of 250 mmol/L with reduced sodium).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<P>ORS formulations with an osmolarity of &#8805; 310 mOsm/L (sodium 90 mmol/L, glucose 111 mmol/L, total osmolarity 311 mmol/L).</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-08 11:28:24 +0000" MODIFIED_BY="Alfred Musekiwa">
<SUBSECTION>
<HEADING LEVEL="4">Primary </HEADING>
<P>Need for unscheduled intravenous infusion.</P>
<P>Symptomatic hyponatraemia as defined by trialists (symptoms include headache, lethargy, confusion, and seizures).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary </HEADING>
<P>Biochemical hyponatraemia as defined by trialists.<BR/>Duration of diarrhoea.<BR/>Stool output in first 24 hours after admission or randomization.<BR/>Vomiting during rehydration.<BR/>Death.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-08 11:28:44 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.<BR/>
</P>
<UL>
<LI>Cochrane Infectious Diseases Group's Specialized Register (April 2011).</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library</I> (Issue 4, 2011).</LI>
<LI>MEDLINE (1966 to April 2011).</LI>
<LI>EMBASE (1974 to April 2011).</LI>
<LI>LILACS (1982 to April 2011).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Organizations </HEADING>
<P>We provided individuals from the following key agencies and organizations with a list of the identified trials and asked for additional completed or ongoing trials: World Health Organization; Centre for Health and Population Research (ICDDR,B); Jawaharlal Nehru Medical College; National Institute of Cholera and Enteric Diseases, and the US Naval Medical Research Unit, Jakarta.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reference lists </HEADING>
<P>We also checked the reference lists of all studies identified by the above methods.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-09 16:48:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-11-09 16:48:17 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Two authors independently screened the results of the search to select potentially relevant studies and applied eligibility criteria using a pre-designed eligibility form based on the inclusion criteria. Corresponding full articles were retrieved and assessed using the eligibility criteria. Each of the articles was scrutinized to ensure that multiple publications from the same trial were included only once. Where there was ambiguity, we sought clarification from the trial authors and re-assessed the articles. We resolved any differences between the eligibility results through discussion. We excluded studies that did not meet the inclusion criteria and stated the reasons in the 'Characteristics of excluded studies'.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-11-09 16:48:54 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Using a specially designed data extraction form, two authors independently extracted information on methods, participants, interventions, and outcomes for each trial. One author entered the data into <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK> and this was independently checked by AM. We scrutinized data sources for multiple publications from the same data sets, referring to the original paper where there were any differences.</P>
<P>We extracted the number of participants randomized in each group and the numbers analyzed for each outcome. For dichotomous data, we extracted the number of events, and for continuous data we extracted the mean and standard deviation or information to estimate the standard deviation. We contacted the publication authors in the case of unclear or missing data. We resolved any differences through discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-11-08 10:30:04 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Two authors (JV and AM) independently assessed the risk of bias of the included studies using the latest Cochrane Collaboration tool for assessing the risk of bias. We followed the guidance to assess whether adequate steps were taken to reduce the risk of bias across six components: sequence generation; allocation concealment; blinding (of participants, personnel and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias. We categorized our judgements as 'yes', 'no' or 'unclear', indicating a low, high or unclear risk of bias respectively. The results were summarized using the 'risk of bias summary' and the 'risk of bias graph', in addition to the risk of bias tables. When necessary, we contacted trial authors for clarification. We resolved any disagreements through discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-12-10 14:16:54 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>We pooled estimates of effect using risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data; and presented these results with 95% confidence intervals (CI). For continuous data that were expressed in different units, we calculated standardized mean difference (SMD).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-11-07 14:07:04 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Trials including more than two comparison groups were split and analyzed as individual pair-wise comparisons.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-11-08 10:30:13 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>If data from the trial reports were insufficient, unclear, or missing, we contacted the trial authors for additional information or clarification. We used the 'intention to treat' principle where there were no missing data. In the case of missing dichotomous data, we still used the 'intention to treat' principle but assumed that all the missing participants did not experience the event. For missing continuous data, we used the available case analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-11-08 10:30:21 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity by visually examining the forest plot to detect overlapping confidence intervals, and used the Chi<SUP>2</SUP> test with a 10% level of significance and the I<SUP>2</SUP> test statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>) with a value of 50% or more to identify substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-11-08 10:30:25 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>We had planned to assess the likelihood of publication bias by examining the forest plot for asymmetry if we found sufficient trials (10 or more).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-11-08 10:30:26 +0000" MODIFIED_BY="[Empty name]">
<P>We analyzed data for glucose-based and rice-based ORS &#8804; 270 separately using <LINK REF="REF-Review-Manager-5" TYPE="REFERENCE">Review Manager 5</LINK>. In the absence of homogeneity of treatment effects, we used a random-effects model of meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-11-08 10:30:30 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>We investigated clinical heterogeneity based on the age of participants by comparing children (&lt; 11 years) with adults (&gt; 11 years), as children may be particularly at risk of developing hyponatraemia.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-11-08 10:30:36 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>We had planned to carry out a sensitivity analysis for risk of bias if we found sufficient trials, in order to investigate the robustness of the results to the quality components.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-09 22:01:00 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-11-08 11:29:14 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Trial selection</HEADING>
<P>We identified 12 studies that appeared to meet our inclusion criteria. However, we excluded five of these studies because one did not evaluate people with cholera, two did not administer ORS &#8804; 270 or ORS &#8805; 310, one did not employ randomization, and one reported cholera and non-cholera data in aggregate only (see 'Characteristics of excluded studies'). We had previously noted two ongoing trials (<I>see</I> <LINK REF="STD-Bangladesh" TYPE="STUDY">Bangladesh</LINK>; <LINK REF="STD-India" TYPE="STUDY">India</LINK>); these two trials have now been completed but we could not obtain their full text articles.</P>
<P>The seven randomized controlled trials included in the analysis were either small in size or only included a small subset of participants with cholera, producing a combined sample size of 797 participants. All trials were published in English-language biomedical journals. We have provided details of these trials in the 'Characteristics of included studies' and have summarized them below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants and location </HEADING>
<P>All trials, including one multicenter study trial (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>), were conducted in low-income countries: Bangladesh (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>), Brazil (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>), India (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>; <LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>), Indonesia (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>), Peru (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>), and Vietnam (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>).</P>
<P>The majority of participants were adults (&gt; 11 years), but three trials (151 participants) assessed children (&lt; 11 years) with cholera (<LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>). Five trials included only,or predominantly, male participants. All trial participants were suffering from a severe degree of dehydration.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions </HEADING>
<P>While all seven trials compared glucose-based ORS &#8804; 270 and ORS &#8805; 310, two trials also included an experimental rice-based ORS &#8804; 270 trial arm (<LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>); the formulations are detailed in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
<P>Before randomization, six trials administered intravenous rehydration solutions such as Ringer's lactate, Dhaka solution, or saline solution to correct severe dehydration (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>). </P>
<P>Six trials treated all participants with antibiotics (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>; <LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>), while the seventh trial administered an antibiotic only when an intercurrent infection occurred (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>).</P>
<P>Four trials reported feeding (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>). <LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK> gave participants bread and bananas immediately after rehydration and standard meals three times daily thereafter. Children in <LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK> were fed curds and bread after they had begun rehydrating and breastfeeding was continued throughout. In <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>, breastfeeding was also continued <I>ad libitum</I> and food appropriate to age was given to children during the maintenance phase. In <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>, noodles were offered immediately after rehydration and meals three times a day were given throughout. The three remaining trials did not report information on feeding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes </HEADING>
<P>The trials assessed the following pre-specified outcomes used in this review: need for unscheduled intravenous infusion; biochemical hyponatraemia; duration of diarrhoea; stool output in first 24 hours after admission or randomization; and vomiting during rehydration. Many of these indicators were measured at different time points (eg 24 hours after study inclusion, total study time). The trials also assessed other outcomes, which are described in the 'Characteristics of included studies'.</P>
<P>None of the trials assessed symptomatic hyponatraemia and death as pre-specified outcomes, although the incidence of clinical signs associated with hyponatraemia was either mentioned in the manuscript text or obtained through correspondence with the authors for five trials (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>). Information on death was reported in the manuscript text of <LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK> and obtained by correspondence with the <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK> trial authors.</P>
<P>We contacted the trial authors if the published reports did not include the outcomes assessed in this review; we received unpublished outcome data for <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK> and <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-08 11:29:26 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>The risk of bias in included studies are summarized in the 'risk of bias graph' (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and the 'risk of bias summary' (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Below we give a detailed explanation of the results.</P>
<ALLOCATION MODIFIED="2011-11-08 11:29:26 +0000" MODIFIED_BY="Alfred Musekiwa">
<SUBSECTION>
<HEADING LEVEL="3">Generation of allocation sequence </HEADING>
<P>All trials were reported as randomized. Six trials employed permuted block randomization for generating the allocation sequence, which we judged as having a low risk of bias (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>); however, none of the trials explicitly mentioned how the sequence was generated. The remaining trial (<LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>) provided insufficient information to enable us to judge whether there was a high or low risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Three trials did not describe methods used to conceal allocation and we judged them as having an unclear risk of bias (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>). Two trials were judged as having a low risk of bias: one (<LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>) used identical packets that were given a number by a faculty colleague not involved in the study, and the other (<LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>) used sachets that were centrally prepared and sequentially numbered according to a randomization code. The remaining two trials (<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>) provided insufficient information to be able to judge them as having a low risk of bias and we therefore judged them as having an unclear risk of bias.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2011-11-08 10:32:14 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Three trials reported that both participants and providers were blinded to treatment assignment (<LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>) by stating that the trials were double-blind and that identical packets were used. These three were therefore judged as having a low risk of bias. Two trials (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>) reported that the trials were double blind but did not describe the blinding, and they were therefore judged as having an unclear risk of bias. Blinding methods were not described in the remaining two trials (<LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>;<LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK> ), which were therefore judged as having an unclear risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-11-08 10:32:19 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>All seven trials were judged as having a low risk of bias since all randomized individuals were included in the final analysis of the seven trials. None of the seven trials had disproportionate numbers of losses to follow-up between the intervention and control arms. Numbers of losses to follow-up were very small in all seven trials.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-11-08 10:32:20 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>No study protocol was found for any of the seven trials and all were therefore judged as having an unclear risk of bias. There were no indications in the trial reports to suspect selective outcome reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-11-08 10:32:21 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>All seven trials were judged as having a low risk of bias as there was no reason to suggest any other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-09 22:01:00 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: ORS &#8804; 270 (glucose-based) versus ORS &#8805; 310 (glucose-based)</HEADING>
<P>Of the seven trials (718 participants) that evaluated ORS &#8804; 270 (glucose-based), three assessed only children (&lt; 11 years; n = 132) and four evaluated only adults (&gt; 11 years; n = 586).</P>
<SUBSECTION>
<HEADING LEVEL="4">Need for unscheduled intravenous fluid infusion:</HEADING>
<P>There was a non-significant tendency towards fewer unscheduled intravenous infusions for those administered ORS &#8804; 270 (glucose-based) (RR 0.86, CI 0.66 to 1.12; n = 616, five trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic hyponatraemia:</HEADING>
<P>There was no symptomatic hyponatraemia detected in the five trials that assessed this outcome (<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>; <LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>; <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Biochemical hyponatraemia</HEADING>
<P>Those receiving ORS &#8804; 270 were almost 70% more likely to develop biochemical hyponatraemia (blood sodium levels &lt; 130 mmol/L) (RR 1.67, CI 1.09 to 2.57; n = 465, four trials; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe biochemical hyponatraemia</HEADING>
<P>Although the point estimate for severe biochemical hyponatraemia (blood sodium levels &lt; 125 mmol/L) was in the same direction as biochemical hyponatraemia, the result was statistically inconclusive (RR 1.58, CI 0.62 to 4.04; n = 465, four trials; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of diarrhoea</HEADING>
<P>For children, we found no statistically significant difference in the duration of diarrhoea between the two groups (MD -2.75 hours, CI -9.79 to 4.29 hours, random effects model, n = 97, two trials, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).<B>
<I> </I>
</B>
</P>
<P>For adults, we detected substantial heterogeneity between the trials (Chi<SUP>2</SUP> = 16.05, df = 3, P = 0.001, I<SUP>2</SUP> = 81%, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Because of this heterogeneity, we report here the individual results for the four trials. We found a statistically significant difference in the duration of diarrhoea between the two formula groups in only one trial (<LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>) (MD -9.70 hours, CI -15.14 to -4.26 hours, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The difference was not statistically significant in the other three trials: <LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK> (MD 3.00 hours, CI -1.16 to 7.16 hours, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>); <LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK> (MD -7.20 hours, CI -16.25 to 1.85 hours, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>); and <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK> (MD 1.00 hour, CI -3.18 to 5.18 hours, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>One study (<LINK REF="STD-Alam-2000" TYPE="STUDY">Alam 2000</LINK>) assessed children and reported the geometric means and standard deviations on a log scale, and so we could not pool it with other studies in a meta-analysis. The geometric mean, standard deviation and total for the ORS &#8804; 270 group were 21.44, 1.32 and 19 respectively, and the corresponding values for the ORS &#8805; 310 group were 19.97, 1.99 and 16 respectively. The mean difference was significant (MD 1.47, CI 0.33 to 2.61).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stool output in first 24 hours after admission or randomization</HEADING>
<P>We found no statistically significant difference in the stool output in the first 24 hours between the two formula groups (SMD -0.13, CI -0.43 to 0.17, random-effects model; n = 581, four trials; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Results from two studies (<LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>; <LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>) were skewed (mean/SD &lt; 2) and therefore the results of the meta-analysis may not be reliable. We detected substantial statistical heterogeneity between the trials (Chi<SUP>2</SUP> = 8.16, df = 3, P 0.04; I<SUP>2</SUP> = 63%). The heterogeneity appears to be attributable either to the skewness detailed above or to the fact that the one trial demonstrating a statistically significant benefit in favour of the ORS &#8804; 270 formula employed a formula with a lower sodium content than used in the other trials (<LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vomiting during rehydration</HEADING>
<P>The proportion of people that vomited during rehydration was similar in the two groups (RR 1.14, CI 0.92 to 1.40; n = 363, two trials; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death</HEADING>
<P>No deaths were reported in the two trials that recorded mortality (<LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>; <LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exploring heterogeneity: children (&lt; 11 years) versus adults (&gt; 11 years)</HEADING>
<P>Subgroup analyses assessing children and adults separately appeared to show differences in the direction of treatment effect estimates for most outcomes. However, as the overall numbers of children were small and the confidence intervals tended to include both point estimates with some degree of overlap, it is difficult to determine whether these represent true differences. While the strength of treatment benefit for the outcome 'need for unscheduled intravenous infusion' appeared to be greater in children receiving ORS &#8804; 270 (glucose-based) (RR 0.57, CI 0.29 to 1.11; n = 93, two trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) than in adults (RR 0.93, CI 0.70 to 1.24; n = 523, three trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) , the point estimate for children has a wider confidence interval and is not statistically significant at the predefined 5% level. Biochemical hyponatraemia may be more problematic for adults receiving the ORS &#8804; 270 formula (RR 1.69, CI 1.06 to 2.69; n = 465, four trials; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), yet this outcome for children was assessed in only one small trial with few events, resulting in a wider confidence interval and a lack of statistical significance (RR 1.58, CI 0.53 to 4.74; n = 39; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). For the two diarrhoeal outcomes where statistically significant heterogeneity was evident, heterogeneity in adults persisted in the subgroup analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: ORS &#8804; 270 (rice-based) versus ORS &#8805; 310 (glucose-based)</HEADING>
<P>Two trials (102 participants) evaluated ORS &#8804; 270 (rice-based).</P>
<SUBSECTION>
<HEADING LEVEL="4">Need for unscheduled intravenous fluid infusion</HEADING>
<P>No information available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic hyponatraemia</HEADING>
<P>No instances of symptomatic hyponatraemia were reported in the one trial that assessed this outcome (<LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Biochemical hyponatraemia</HEADING>
<P>While the point estimates suggest a reduced risk of biochemical hyponatraemia (blood sodium levels &lt; 130 mmol/L) for those receiving ORS &#8804; 270 (rice-based), these findings are not statistically significant (RR 0.66, CI 0.26 to 1.69; n = 102, two trials; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe hyponatraemia</HEADING>
<P>Severe biochemical hyponatraemia (blood sodium levels &lt; 125 mmol/L) was similar between the two groups; the confidence interval around the risk ratio is wide, reflecting the small number of events for this outcome (RR 0.35, CI 0.02 to 8.10; n = 102, two trials; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of diarrhoea</HEADING>
<P>There was a statistically significant reduction in the duration of diarrhoea for those receiving the ORS &#8804; 270 (rice-based) formula (MD -11.42 hours, CI -13.80 to -9.04; n = 102, two trials; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcomes</HEADING>
<P>None of the trials evaluated or reported on the other outcomes of interest.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exploring heterogeneity: children (&lt; 11 years) versus adults (&gt; 11 years)</HEADING>
<P>One small trial was available for each subgroup for three outcomes of interest. For biochemical hyponatraemia, there was no statistically significant heterogeneity between the two subgroups (Chi<SUP>2</SUP> = 1.11, df = 1, P = 0.29; I<SUP>2</SUP>=10%, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). For severe biochemical hyponatraemia, there was no heterogeneity to be assessed as one of the trials had no events for both treatment arms and was therefore inestimable (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). For duration of diarrhoea, there was considerable heterogeneity between the two subgroups (Chi<SUP>2</SUP> = 10.23, df = 1, P = 0.001; I<SUP>2</SUP>=90%, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-08 11:32:38 +0000" MODIFIED_BY="[Empty name]">
<P>Our review draws attention to the paucity of evidence on the effects of ORS &#8804; 270 (glucose-based) compared with ORS &#8805; 310 for treating people with cholera, with only seven trials evaluating 718 participants.</P>
<P>We intended to examine the safety of glucose-based ORS &#8804; 270 for cholera by measuring the incidence of symptomatic hyponatraemia, as low blood sodium levels may be transient and therefore not necessarily result in serious illness. The 2001 WHO/UNICEF meeting of ORS formulation experts highlighted the importance of this outcome in people receiving treatment for cholera (<LINK REF="REF-WHO-2001b" TYPE="REFERENCE">WHO 2001b</LINK>). An observational study found that the risk of symptoms associated with hyponatraemia in patients treated with ORS &#8804; 270 was minimal and did not increase with the change in formulation (<LINK REF="REF-Alam-2006" TYPE="REFERENCE">Alam 2006</LINK>). As none of the trials found or explicitly evaluated symptomatic hyponatraemia, we could not assess this outcome. Instead, we measured the incidence of biochemical hyponatraemia. Asymptomatic hyponatraemia, while not providing a definitive marker for treatment failure, provides an important measure of potential risk for people with cholera.</P>
<P>We found that participants receiving ORS &#8804; 270 were at greater risk of developing biochemical hyponatraemia (blood sodium levels &lt; 130 mmol/L); however, the relatively few cases of severe biochemical hyponatraemia (blood sodium levels &lt; 125 mmol/L) precludes firm conclusions regarding this outcome. These findings should, nevertheless, alert clinicians to the need for vigilance concerning the risk of hyponatraemia in non-trial settings.</P>
<P>For other outcomes, such as unscheduled intravenous infusion, stool output, vomiting, and duration of diarrhoea, there was little difference in effect between the two types of formulae. However, as most of the available trials are small with few events, they may have insufficient power to demonstrate important clinical differences even after pooling the results.</P>
<P>In separate analyses of two trials (102 participants) comparing ORS &#8804; 270 (rice-based) with ORS &#8805; 310 (glucose-based), we found no statistically significant differences except for the duration of diarrhoea, which was substantially shorter in the group receiving ORS &#8804; 270 (rice-based). A similar finding was reported in a systematic review that compared rice-based ORS with glucose-based ORS &#8805; 310 formulas in people with diarrhoea (<LINK REF="REF-Fontaine-1998" TYPE="REFERENCE">Fontaine 1998</LINK>).</P>
<P>Data available for assessing the safety and efficacy ORS &#8804; 270 in children with cholera are also extremely limited, making it difficult to draw firm conclusions. Only one trial reported the risk of biochemical hyponatraemia in children (<LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>) and it showed a trend favouring the ORS &#8805; 310 formula, but this finding was not statistically significant.</P>
<P>WHO and UNICEF currently recommend formulations with a total osmolarity of 245 mmol/L for treating diarrhoea. It is not known, however, whether using ORS &#8804; 270 is appropriate in cholera-endemic regions, where the balance between benefit and harm can be tenuous. Logistically, having one ORS formula is easier. However, the increased risk of biochemical hyponatraemia in those receiving ORS &#8804; 270 solutions is of concern. Even though there were no instances of symptomatic hyponatraemia or death, the total patient experience in the trials is very small and these effects cannot be ruled out under wider practice conditions. Moreover, careful monitoring of blood sodium levels may be difficult in areas where healthcare resources are limited, especially during complex emergencies and large epidemics. Further trials in both adults and children with cholera should be undertaken to clarify these issues.</P>
<SUBSECTION>
<HEADING LEVEL="2">Quality of evidence</HEADING>
<P>The quality of evidence was assessed using the GRADE methodology. Overall the quality is moderate, meaning that further research is likely to have an important impact on our confidence in the estimate of effect, and may change the estimate. See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-11-08 10:37:22 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-11-08 10:37:18 +0000" MODIFIED_BY="[Empty name]">
<P>In people with cholera, ORS &#8804; 270 results in more patients developing biochemical hyponatraemia, with no detectable benefits such as the need for unscheduled intravenous infusion, duration of diarrhoea, or stool volume, compared with the older ORS &#8805; 310 formula. The increased risk of low blood sodium levels could have major implications in resource-constrained settings where clinicians may not have monitoring facilities and must rely on presumptive diagnosis. This review found no serious clinical consequences related to hyponatraemia in trial participants, but it is important to note that total patient experience in the existing trials is small.</P>
<P>WHO and UNICEF currently recommend an ORS &#8804; 270 formulation for treating dehydration caused by all types of diarrhoea. While it may be easier to administer a single ORS formulation worldwide, the potential harms and limited evidence of improved efficacy for people with cholera should be kept in mind.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-11-08 10:37:22 +0000" MODIFIED_BY="[Empty name]">
<P>Further randomized controlled trials are needed to assess the balance between benefit and harm associated with the use of ORS &#8804; 270 in people with cholera. These trials should be large enough to adequately assess important outcomes, including symptomatic hyponatraemia and death.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-11-09 16:45:36 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>The protocol for this review was developed during the Mentorship Programme organized by the Cochrane Infectious Diseases Group in November 2001. The UK Department for International Development supports this Programme through the Effective Health Care Alliance Programme at the Liverpool School of Tropical Medicine.</P>
<P>We would like to thank Colleen Murphy who first initiated the review, and was the guarantor on the first published version. Additionally we would like to acknowledge Dr Seokyung Hahn, who contributed to the original review design and analysis.</P>
<P>We wish to thank Professor Paul Garner for his guidance in developing the protocol. We are also grateful to trial authors who provided us with clarifications and unpublished data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-11-09 16:50:07 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Colleen Murphy (CM) initiated the review and developed the eligibility and data extraction forms, with Seokyung Hahn (SH) and Jimmy Volmink (JV) providing input. CM and JV selected the trials for inclusion in the initial version of the review. CM, JV and Alfred Musekiwa (AM) extracted the data and assessed trial quality, and CM contacted authors for additional information for the first published version of the review. CM and AM entered the data and conducted the analysis. CM wrote the first draft of the review, with all reviewers contributing to the final text and analysis. AM responded to editor's comments and drafted this review update in line with RevMan 5.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-11-08 10:37:42 +0000" MODIFIED_BY="[Empty name]">
<P>The title has been changed to 'Oral rehydration solution for treating cholera: ORS &#8804; 270 mOsm/L solutions vs ORS &#8805; 310 mOsm/L solutions'. The secondary outcome stool volume was changed to stool output to accommodate some stool weight measurements as reported by other trials.</P>
<P>We had planned the following analyses but they were not appropriate for the data available: (1) analysis of geometric means and standard deviation using log normal approximation; (2) analysis of time-to-event or censored data, when available, to estimate the log hazards ratio and its variance within each trial, using methods proposed by <LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>; (3) examination of funnel plots for asymmetry indicative of publication bias; and (4) sensitivity analysis to determine the degree to which the results were influenced by the adequacy of allocation concealment.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2011-11-09 22:01:27 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-08 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-11-08 10:44:40 +0000" MODIFIED_BY="Alfred Musekiwa">
<INCLUDED_STUDIES MODIFIED="2011-11-08 10:43:45 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alam-1999" NAME="Alam 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alam NH, Majumder RN, Fuchs GJ</AU>
<TI>Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double-blind clinical trial. CHOICE study group</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9175</NO>
<PG>296-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alam-2000" NAME="Alam 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alam S, Afzal K, Maheshwari M, Shukla I</AU>
<TI>Controlled trial of hypo-osmolar versus World Health Organization oral rehydration solution</TI>
<SO>Indian Pediatrics</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>9</NO>
<PG>952-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhattacharya-1998" NAME="Bhattacharya 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bhattacharya MK, Bhattacharya SK, Dutta D, Deb AK, Deb M, Dutta A, et al</AU>
<TI>Efficacy of oral hyposmolar glucose-based and rice-based oral rehydration salt solution in the treatment of cholera in adults</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>2</NO>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Choice-2001" NAME="Choice 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>CHOICE Study Group</AU>
<TI>Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of a reduced osmolarity oral rehydration salts solution in children with acute watery diarrhea</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<NO>4</NO>
<PG>613-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dutta-2000" NAME="Dutta 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dutta D, Bhattacharya MK, Deb AK, Sarkar D, Chatterjee A, Biswas AB, et al</AU>
<TI>Evaluation of oral hypo-osmolar glucose-based and rice-based oral rehydration solutions in the treatment of cholera in children</TI>
<SO>Acta Paediatrica</SO>
<YR>2000</YR>
<VL>89</VL>
<NO>7</NO>
<PG>787-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Faruque-1996" MODIFIED="2011-11-08 10:43:31 +0000" MODIFIED_BY="[Empty name]" NAME="Faruque 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-11-08 10:43:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Faruque AS, Mahalanabis D, Hamadani JD, Zetterstrom R</AU>
<TI>Reduced osmolarity oral rehydration salt in cholera</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>1</NO>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pulungsih-2006" MODIFIED="2011-11-08 10:43:45 +0000" MODIFIED_BY="[Empty name]" NAME="Pulungsih 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-11-08 10:43:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pulungsih SP, Punjabi NH, Rafli K, Rifajati A, Kumala S, Simanjuntak CH, et al</AU>
<TI>Standard WHO-ORS versus reduced osmolarity ORS in the management of cholera patients</TI>
<SO>Journal of Health, Population and Nutrition</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>1</NO>
<PG>107-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-08 10:43:58 +0000" MODIFIED_BY="Alfred Musekiwa">
<STUDY DATA_SOURCE="PUB" ID="STD-Bhan-1995" NAME="Bhan 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bhan MK, Chea Woo E, Fontaine O, Maulen-Radoven I, Pierce NF, Ribeiro Jr H, et al</AU>
<TI>Multicentre evaluation of reduced-osmolarity oral rehydration salts solution</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<NO>8945</NO>
<PG>282-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dutta-2001" MODIFIED="2011-11-08 10:43:58 +0000" MODIFIED_BY="Alfred Musekiwa" NAME="Dutta 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-11-08 10:43:58 +0000" MODIFIED_BY="Alfred Musekiwa" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dutta P, Mitra U, Manna B, Niyogi SK, Roy K, Mondal C, et al</AU>
<TI>Double blind, randomised controlled clinical trial of hypo-osmolar oral rehydration salt solution in dehydrating acute diarrhoea in severely malnourished (marasmic) children</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>84</VL>
<NO>3</NO>
<PG>237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutman-1969" NAME="Gutman 1969" YEAR="1969">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gutman RA, Drutz DJ, Whalen GE, Watten RH</AU>
<TI>Double blind fluid therapy evaluation in pediatric cholera</TI>
<SO>Pediatrics</SO>
<YR>1969</YR>
<VL>44</VL>
<NO>6</NO>
<PG>922-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahalanabis-1974" NAME="Mahalanabis 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mahalanabis D, Sack RB, Jacobs B, Mondal A, Thomas J</AU>
<TI>Use of an oral glucose-electrolyte solution in the treatment of paediatric cholera--a controlled study</TI>
<SO>Journal of Tropical Pediatrics and Environmental Child Health</SO>
<YR>1974</YR>
<VL>20</VL>
<NO>2</NO>
<PG>82-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nalin-1968" MODIFIED="2010-12-18 20:31:42 +0000" MODIFIED_BY="Alfred Musekiwa" NAME="Nalin 1968" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nalin DR, Cash RA, Islam R, Molla M, Phillips RA</AU>
<TI>Oral maintenance therapy for cholera in adults</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>2</VL>
<NO>7564</NO>
<PG>370-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-12-18 20:31:42 +0000" MODIFIED_BY="Alfred Musekiwa"/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2011-11-08 10:44:40 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bangladesh" MODIFIED="2011-11-08 10:44:19 +0000" MODIFIED_BY="[Empty name]" NAME="Bangladesh" YEAR="">
<REFERENCE MODIFIED="2011-11-08 10:44:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<TI>To investigate further the impact of low osmolarity oral rehydration solution on the incidence and prevalence of hyponatraemia in diarrhoeic patients, especially those with cholera [Awaiting details]</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-India" MODIFIED="2011-11-08 10:44:40 +0000" MODIFIED_BY="[Empty name]" NAME="India" YEAR="">
<REFERENCE MODIFIED="2011-11-08 10:44:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<TI>Phase IV controlled trial to investigate further the impact of low osmolarity oral rehydration solution on the incidence and prevalence of hyponatraemia in diarrhoeic patients, especially those with cholera [Awaiting details]</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-08 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-08 12:13:00 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alam-2006" MODIFIED="2011-11-08 10:44:50 +0000" MODIFIED_BY="[Empty name]" NAME="Alam 2006" TYPE="JOURNAL_ARTICLE">
<AU>Alam NH, Yunus M, Faruque ASG, Gyr N, Sattar S, Parvin S, et al</AU>
<TI>Symptomatic Hyponatremia During Treatment of Dehydrating Diarrheal Disease With Reduced Osmolarity Oral Rehydration Solution</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<NO>5</NO>
<PG>567-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2004" NAME="Duggan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Duggan C, Fontaine O, Pierce NF, Glass RI, Mahalanabis D, Alam NH, et al</AU>
<TI>Scientific rationale for a change in the composition of oral rehydration solution</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>21</NO>
<PG>2628-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fontaine-1998" MODIFIED="2011-11-08 12:13:00 +0000" MODIFIED_BY="[Empty name]" NAME="Fontaine 1998" TYPE="COCHRANE_REVIEW">
<AU>Fontaine O, Gore SM, Pierce NF</AU>
<TI>Rice-based oral rehydration solution for treating diarrhoea</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-11-08 12:13:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-08 12:13:00 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001264. DOI: 10.1002/14651858.CD001264.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuchs-2001" NAME="Fuchs 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs GJ</AU>
<TI>A better oral rehydration solution? An important step, but not a leap forward</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7304</NO>
<PG>59-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guarino-2000" NAME="Guarino 2000" TYPE="JOURNAL_ARTICLE">
<AU>Guarino A, Albano F, Guandalini S; Working Group on Acute Gastroenteritis</AU>
<TI>Oral rehydration: Toward a real solution</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2000</YR>
<VL>33 Suppl 2</VL>
<PG>2-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hahn-2002" MODIFIED="2011-11-08 10:45:08 +0000" MODIFIED_BY="[Empty name]" NAME="Hahn 2002" TYPE="COCHRANE_REVIEW">
<AU>Hahn S, Kim J, Garner P</AU>
<TI>Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-03 11:52:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 11:52:59 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD002847. DOI: 10.1002/14651858.CD002847"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-11-03 11:53:07 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2011-11-03 11:53:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Nalin-2004" NAME="Nalin 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nalin DR, Hirschhorn N, Greenough W, Fuchs GJ, Cash RA</AU>
<TI>Clinical concerns about reduced-osmolarity oral rehydration solution</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>21</NO>
<PG>2632-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival end-points</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quotah-1999" NAME="Quotah 1999" TYPE="OTHER">
<AU>Quotah E</AU>
<TI>A not-so-simple solution: cholera</TI>
<SO>Harvard Public Health Review (http://www.hsph.harvard.edu/review/summer_solution.shtml)</SO>
<YR>Summer 1999 (Accessed 29 July 2004)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rabbani-2000" MODIFIED="2009-03-02 21:40:30 +0000" MODIFIED_BY="[Empty name]" NAME="Rabbani 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rabbani GH</AU>
<TI>The search for a better oral rehydration solution for cholera</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<NO>5</NO>
<PG>345-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-5" MODIFIED="2010-12-18 20:32:15 +0000" MODIFIED_BY="Alfred Musekiwa" NAME="Review Manager 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2009</YR>
<EN>5.0.23 for Windows</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Oxford, England</CY>
<MD>CD-ROM and Internet</MD>
<IDENTIFIERS MODIFIED="2010-12-18 20:32:15 +0000" MODIFIED_BY="Alfred Musekiwa"/>
</REFERENCE>
<REFERENCE ID="REF-Sack-2004" NAME="Sack 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sack DA, Sack RB, Nair GB, Siddique AK</AU>
<TI>Cholera</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9404</NO>
<PG>223-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2011-11-08 10:45:23 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2000" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Cholera: can rehydration therapy be improved?</TI>
<SO>WHO Drug Information</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>2</NO>
<PG>88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001a" NAME="WHO 2001a" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Cholera, 2000</TI>
<SO>Weekly Epidemiological Record</SO>
<YR>2001</YR>
<VL>76</VL>
<NO>31</NO>
<PG>233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001b" NAME="WHO 2001b" TYPE="BOOK">
<AU>World Health Organization. Department of Child and Adolescent Health and Development</AU>
<SO>Reduced osmolarity: oral rehydration salts (ORS) formulation. A report from a meeting of experts jointly organised by UNICEF and WHO: UNICEF House, New York, USA, 18 July 2001</SO>
<YR>2002</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" NAME="WHO 2002" TYPE="BOOK">
<AU>World Health Organization Director-General's Office Communications Office</AU>
<SO>New formula for oral rehydration salts will save millions of lives [Press release]</SO>
<YR>8 May 2002</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2008" MODIFIED="2011-11-08 10:45:31 +0000" MODIFIED_BY="Alfred Musekiwa" NAME="WHO 2008" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organisation</AU>
<TI>Cholera, 2007</TI>
<SO>Weekly Epidemiological Record</SO>
<YR>2008</YR>
<VL>83</VL>
<NO>31</NO>
<PG>269</PG>
<IDENTIFIERS MODIFIED="2009-03-02 21:28:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-11-08 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Murphy-2004" MODIFIED="2011-11-08 12:15:14 +0000" MODIFIED_BY="[Empty name]" NAME="Murphy 2004" TYPE="COCHRANE_REVIEW">
<AU>Murphy C, Hahn S, Volmink J</AU>
<TI>Reduced osmolarity oral rehydration solution for treating cholera</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-11-08 12:15:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-08 12:15:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD003754. DOI: 10.1002/14651858.CD003754.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-08 10:51:23 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-08 10:51:23 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-08 10:38:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alam-1999">
<CHAR_METHODS MODIFIED="2011-11-08 10:37:45 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized controlled trial.</P>
<P>Duration:1 year 10 months, from July 1995 to May 1997.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:37:50 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants: 300 randomized (168 men; 131 women).</P>
<P>Inclusion criteria: adult men and women aged 15 to 55 years; history of acute watery diarrhoea for &lt; 24 hours before admission; severe dehydration; stool positive for <I>Vibrio cholerae</I> under dark-field illumination; successful rehydration with intravenous infusion within 6 hours of admission.</P>
<P>Exclusion criteria: suspected pregnancy; bloody diarrhoea; systemic infection requiring intravenous antibiotics; inability to rehydrate with intravenous infusion within 6 hours after admission.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:37:56 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
<P>Co-interventions: erythromycin (500 mg orally every 6 hours for 3 days).</P>
<P>Food: bread, banana (immediately after rehydration), and standard meals (rice, fish, or meat, vegetables and lentils) 3 times daily.</P>
<P>Water: given as desired, usually with meals.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:38:05 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>(1) Need for unscheduled intravenous infusion.*<BR/>(2) Duration of diarrhoea (after randomization, hours).*<BR/>(3) Vomiting during rehydration during initial 24 hours.*<BR/>(4) Stool weight (g/kg bodyweight) in first 24 hours after admission/randomization.*<BR/>(5) Total stool weight, g/kg body weight.<BR/>(6) Urine volume during initial 24 hours (ml/kg bodyweight).<BR/>(7) Total urine volume (ml/kg body weight).<BR/>(8) Initial 24 hours ORS intake (ml/kg body weight).<BR/>(9) Total ORS intake (ml/kg body weight).<BR/>(10) Initial 24 hours water intake (ml/kg body weight).<BR/>(11) Total water intake (ml/kg body weight).<BR/>(12) Biochemical hyponatraemia (&lt; 130 mmol/L) 24 hours after admission.*<BR/>(13) Biochemical hyponatraemia (&lt; 125 mmol/L) 24 hours after admission.*<BR/>(14) Biochemical hyponatraemia (&lt; 120 mmol/L) 24 hours after admission.*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-08 10:38:07 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Bangladesh. (Trial started at two sites, in Bangladesh and Indonesia, but it was discontinued at the latter due to inadequate participant supervision. No data from Indonesia included in the analysis.)</P>
<P>Date: July 1995 to May 1997.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 10:38:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alam-2000">
<CHAR_METHODS MODIFIED="2011-11-08 10:38:09 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized controlled trial.</P>
<P>Duration: Unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:38:18 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Number of participants: 179 randomized (cholera proved by culture in 35).</P>
<P>Inclusion criteria: all children with acute diarrhoea (&lt; four days duration) with dehydration that met one of the following: non-cholera diarrhoea, aged between three months and five years, children above three months with clinical suspicion of cholera.</P>
<P>Exclusion criteria: children with clinical evidence of systemic infection; encephalopathy; electrolyte imbalance; convulsions; invasive diarrhoea.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:38:23 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
<P>75 ml/kg ORS in first 4 hours.</P>
<P>Food: curds and banana feeds offered once hydration improved.</P>
<P>Co-intervention: single dose of doxycycline (8 mg/kg) administered to all with clinical suspicion of cholera or stool positive for motiles (repeated if vomited within 0.5 hour of administration).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Need for unscheduled intravenous infusion.*<BR/>(2) Overall diarrhoea frequency (stool/4 hour).<BR/>(3) Overall ORS consumed (L).<BR/>(4) Overall diarrhoea duration.*<BR/>(5) Weight gain.<BR/>(6) Caloric intake (kcal/kg/day).<BR/>(7) Serum sodium (meq/L).<BR/>(8) Urine output (boys) (ml/kg/h).<BR/>(9) Intravenous fluids (ml/kg).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-02 14:44:57 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Diarrhea Training and Treatment Unit, Aligarh, India.</P>
<P>Date: unclear.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 10:38:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bhattacharya-1998">
<CHAR_METHODS MODIFIED="2011-11-08 10:38:32 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized clinical trial.</P>
<P>Duration: two years and eight months, from August 1993 to March 1996.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:38:34 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants: 123 randomized.</P>
<P>Inclusion criteria: adult men; acute watery diarrhoea for &lt; 24 hours; severe dehydration; severe cholera.</P>
<P>Exclusion criteria: received antibiotics before hospitalization; received intravenous fluid before hospitalization; systemic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:38:40 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8804; 270 (rice-based).</P>
<P>(3) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
<P>Co-interventions: doxycycline (300 mg) as a single dose after correction of initial dehydration and when vomiting stops.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:38:43 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Duration of diarrhoea (h).*<BR/>(2) Total stool output (L).<BR/>(3) Number (%) of participants with 24-hour serum sodium level of 125 to 130 mmol/L.*<BR/>(4) Number (%) of participants with 24-hour serum sodium level of &gt; 130 mmol/L.*<BR/>(5) Total ORS intake (L).<BR/>(6) Body weight increment (%).<BR/>(7) Total fluid requirement (L).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-08 10:38:44 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Infectious Diseases Hospital, Calcutta, India.</P>
<P>Date: August 1993 to March 1996.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 10:51:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choice-2001">
<CHAR_METHODS MODIFIED="2011-11-08 10:38:48 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized clinical trial.</P>
<P>Duration: one year and eight months, from June 1995 to February 1997.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:38:54 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants: 675 randomized (58 with cholera).</P>
<P>Inclusion criteria: male children aged one to 24 months; diarrhoea for &lt; 72 hours (with passage of three or more watery stools in the 24 hours before admission); signs of some or severe dehydration.</P>
<P>Exclusion criteria: bloody diarrhoea; clinical signs of systemic infection that required intravenous antibiotic therapy; severe malnutrition defined as admission weight for height &lt; 65% of the National Center for Health Statistics standard (to account for rehydration); presence of obvious edema.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:38:58 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
<P>Co-interventions: breastfeeding <I>ad libitum</I>; food appropriate for age during maintenance phase; water <I>ad libitum</I> during maintenance phase; antibiotics if developed intercurrent infections after enrolment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:39:02 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Stool output (g/kg) at 24 hours.*<BR/>(2) Total stool output (g/kg).<BR/>(3) ORS intake (ml/kg) at 24 hours.<BR/>(4) Total ORS intake (ml/kg).<BR/>(5) Vomiting in first 24 hours (%).<BR/>(6) Vomitus 10 g/kg (%).<BR/>(7) Unscheduled intravenous therapy in first 24 hours (%).*<BR/>(8) Children with serum sodium at 24 hours (%): &lt; 130 mmol/L; &lt; 125 mmol/L.*<BR/>(9) Duration of diarrhoea.*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-08 10:51:23 +0000" MODIFIED_BY="[Empty name]">
<P>Location (five centres): (1) Centre for Health and Population Research, Bangladesh (ICDDR,B).<BR/>(2) Centro Pediatrico Professor Hosannah de Oliveira-Universidade Federal da Bahia, Salvador, Brazil.<BR/>(3) All India Institute of Medical Sciences and Kasturba Hospital, New Delhi, India.<BR/>(4) Hospital Nacional Cayetano Heredia, Lima, Peru.<BR/>(5) Children's Hospital No. 1, Ho Chi Minh City, Vietnam.</P>
<P>Date: June 1995 to February 1997.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 10:39:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dutta-2000">
<CHAR_METHODS MODIFIED="2011-11-08 10:39:10 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized clinical trial.</P>
<P>Duration: two years and nine months, from August 1995 to May 1998.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:39:13 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants: 58 randomized.</P>
<P>Inclusion criteria: male children aged two to 10 years; stool positive for <I>Vibrio cholerae</I>; acute watery diarrhoea &lt; 24 hours duration; signs of severe dehydration (sunken eyes, very dry mouth and tongue, absence of tears, loss of skin elasticity, diminished urine output).</P>
<P>Exclusion criteria: antibiotic use; received intravenous fluid; systemic illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:39:21 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8804; 270(rice-based).</P>
<P>(3) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
<P>Co-interventions: tetracycline tablet (50 mg/kg/day of body weight in four divided doses for three days after correction of initial dehydration).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Incidence of symptomatic hyponatraemia.*<BR/>(2) Total stool output (L).<BR/>(3) Total ORS intake (L).<BR/>(4) Body weight (kg).<BR/>(5) Serum sodium level (mmol/L).<BR/>(6) Serum sodium level &lt; 125 mmol/L.*<BR/>(7) Serum sodium level 125 to 130 mmol/L.*<BR/>(8) Duration of diarrhoea.*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: Infectious Diseases Hospital, Calcutta, India.</P>
<P>Date: August 1995 to May 1998.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 10:40:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Faruque-1996">
<CHAR_METHODS MODIFIED="2011-11-08 10:39:28 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized clinical trial.</P>
<P>Duration: six months, during the second half of 1994.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:39:30 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: males aged 15 to 49 presenting severe cholera-like diarrhoea of &lt; 24 hours duration; severe dehydration requiring intravenous therapy (patients with clinical signs of dehydration who had postural hypotension with a feeble or imperceptible radial pulse and systolic blood pressure of less than 90 mmHg); dark-field positive for <I>Vibrio cholerae</I>.</P>
<P>Exclusion criteria: no concurrent illness or recognized chronic disease; recent history of antibiotic use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:39:57 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
<P>Co-interventions: intravenous therapy to correct dehydration over a period of three to four hours; saline solution (sodium 133, chloride 98, potassium 13, acetate 48 mmol/L); erythromycin (500 mg, six hourly); additional intravenous therapy (rapidly administered) for patients who went into negative fluid balance and where clinical signs of dehydration reappeared (saline solution consisting of sodium 133, chloride 98, potassium 13, acetate 48 mmol/L).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Need for unscheduled intravenous infusion.*<BR/>(2) Stool volume in first 24 hours after admission/randomization (ml/kg).*<BR/>(3) Duration of diarrhoea (hours).*<BR/>(4) Vomiting during rehydration (0 to 24 hours and 24 to 48 hours).*<BR/>(5) Stool output (ml/kg) 24 to 48 hours.<BR/>(6) Stool output (ml/kg) 0 to 48 hours.<BR/>(7) ORS intake (ml/kg) 0 to 24 hours.<BR/>(8) ORS intake (ml/kg) 24 to 48 hours.<BR/>(9) ORS intake (ml/kg) 0 to 48 hours.<BR/>(10) Urine output (ml/kg) 0 to 24 hours.<BR/>(11) Urine output (ml/kg) 24 to 48 hours.<BR/>(12) Urine output (ml/kg) 0 to 48 hours.<BR/>(13) Serum sodium (mmol/L) at 24 hours and 48 hours.<BR/>(14) Serum potassium (mmol/L) at 24 hours and 48 hours.<BR/>(15) Serum chloride (mmol/L) at 24 hours and 48 hours.<BR/>(16) Serum total carbon dioxide at 24 hours and 48 hours.<BR/>(17) Number of patients with a 24-hour serum sodium of &lt; 125 mmol/L, 125 to 130 mmol/L, and &gt; 130 mmol/L.*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: International Centre for Diarrhoel Disease Research, Bangladesh (ICDDR,B).</P>
<P>Date: second half of 1994.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 10:40:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pulungsih-2006">
<CHAR_METHODS MODIFIED="2011-11-08 10:40:17 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized clinical trial.</P>
<P>Duration: one year, from January 1994 to January 1995.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:40:21 +0000" MODIFIED_BY="[Empty name]">
<P>Number of participants: 160 randomized.</P>
<P>Inclusion criteria: Patients aged 12 to 60 with acute watery diarrhoea for less than 24 hours prior to admission; clinical signs of severe dehydration according to WHO guidelines; stool output less than 5 g/kg/h during initial intravenous infusion; no visible blood in stool.</P>
<P>Exclusion criteria: Pregnant women; patients with systemic infections or other diseases requiring specific additional treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:40:24 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270 (glucose-based).</P>
<P>(2) ORS &#8805; 310 (glucose-based).</P>
<P>See Additional Table 2 for the ORS compositions.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 10:40:30 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Patients requiring additional intravenous fluid infusion (%).*<BR/>(2) Stool output in first 24 hours after admission/randomization (ml).*<BR/>(3) Total stool output (ml).<BR/>(4) Duration of diarrhoea after randomization (h).*<BR/>(5) Volume of vomiting 24 hours after randomization (ml).<BR/>(6) Total volume of vomiting (ml).<BR/>(7) Urine output 24 hours after randomization (ml).<BR/>(8) Total urine output (ml).<BR/>(9) ORS intake 24 hours after randomization (ml).<BR/>(10) Total ORS intake (ml).<BR/>(11) Symptomatic hyponatraemia<BR/>(12) Asymptomatic hyponatraemia<BR/>(13) Serum potassium concentrations<BR/>(14) Asymptomatic hypokalaemia (serum potassium &lt;3 mEq/ml)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Location: Prf. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia.</P>
<P>Date: January 1994 to January 1995.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Allocation concealment: A = adequate; B = unclear (see 'Methods of the review'); ORS: oral rehydration solution; *outcomes assessed in this review.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-11-08 10:40:45 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bhan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants did not have cholera.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 10:40:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dutta-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 10:40:38 +0000" MODIFIED_BY="[Empty name]">
<P>Included participants with cholera and non-cholera diarrhoea. Results reported in aggregate; we have requested the disaggregated data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 10:40:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gutman-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 10:40:41 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were not administered either ORS &#8804; 270 or ORS &#8805; 310.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 10:40:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahalanabis-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 10:40:44 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were not administered either ORS &#8804; 270 or ORS &#8805; 310.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-08 10:40:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nalin-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-08 10:40:45 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomized trial. Participants were not administered ORS &#8804; 270.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ORS: oral rehydration solution.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-11-08 10:41:05 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-11-08 10:40:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bangladesh">
<CHAR_STUDY_NAME MODIFIED="2011-11-08 10:40:51 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>To investigate further the impact of low osmolarity ORS on the incidence and prevalence of hyponatraemia in diarrhoeic patients, especially those with cholera</P>
<P>(Study ID: NCT00672308).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-11-08 10:40:52 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Randomized controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Not known.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:40:54 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270.</P>
<P>(2) ORS &#8805; 310.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not known.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not known.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Centre for Health and Population Research, (ICDDR,B).</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-08 10:40:54 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Location: Dhaka, Bangladesh.</P>
<P>Awaiting details.</P>
<P>Study ID: NCT00672308.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2011-11-08 10:41:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-India">
<CHAR_STUDY_NAME MODIFIED="2011-11-08 10:41:00 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Phase IV controlled trial to investigate further the impact of low osmolarity ORS on the incidence and prevalence of hyponatraemia in diarrhoeic patients, especially those with cholera </P>
<P>(Study ID: NCT00490932).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-11-08 10:41:01 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Surveillance study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 10:41:02 +0000" MODIFIED_BY="[Empty name]">
<P>About 20,000 patients (adults and children) with diarrhoea (non-cholera and cholera).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-08 10:41:04 +0000" MODIFIED_BY="[Empty name]">
<P>(1) ORS &#8804; 270.</P>
<P>(2) ORS &#8805; 310.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not known.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not known.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Awaiting details.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-08 10:41:05 +0000" MODIFIED_BY="Alfred Musekiwa">
<P>Location: Calcutta, India.</P>
<P>Awaiting details.</P>
<P>Study ID: NCT00490932.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ORS: oral rehydration solution</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-11-08 10:40:33 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-08 10:40:13 +0000" MODIFIED_BY="Alfred Musekiwa" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:44:16 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Alam-1999">
<DESCRIPTION>
<P>"The randomization list ... was prepared ... by use of permuted blocks of variable length."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 10:38:27 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Alam-2000">
<DESCRIPTION>
<P>"randomized and serially given a number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 11:45:36 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Bhattacharya-1998">
<DESCRIPTION>
<P>"randomly assigned" based on randomization chart and used permuted blocks of random numbers of block length 16.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:40:17 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Choice-2001">
<DESCRIPTION>
<P>"The randomization list ... were prepared ... using permuted blocks of variable length."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:24:08 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Dutta-2000">
<DESCRIPTION>
<P>"Treatment allocation was random, according to a random number chart prepared using permuted blocks of random numbers of block length 9."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 10:40:13 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Faruque-1996">
<DESCRIPTION>
<P>"randomization done in blocks."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 11:46:27 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Pulungsih-2006">
<DESCRIPTION>
<P>"randomization list" with "random permuted blocks of variable length" used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-03 11:46:13 +0000" MODIFIED_BY="Alfred Musekiwa" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-03 06:17:18 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1999">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-20 15:23:04 +0100" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Alam-2000">
<DESCRIPTION>
<P>"Since this was a double blind clinical trial, identical packets containing 5 sachets of the salts were randomized and serially given a number by a faculty colleague not involved in the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:53:23 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Bhattacharya-1998">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:41:41 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Choice-2001">
<DESCRIPTION>
<P>"The randomization list and numbered ORS packets (...) were prepared at the WHO (Geneva, Switzerland)..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:26:41 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Dutta-2000">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 11:46:13 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Faruque-1996">
<DESCRIPTION>
<P>"serially numbered boxes of ORS packets prepared by hospital pharmacy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 11:04:02 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Pulungsih-2006">
<DESCRIPTION>
<P>Sachets centrally prepared; sequentially numbered and correspond to the randomization code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-08 10:40:32 +0000" MODIFIED_BY="Alfred Musekiwa" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 10:38:07 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1999">
<DESCRIPTION>
<P>"double-blind" but method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-19 07:36:23 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Alam-2000">
<DESCRIPTION>
<P>"Since this was a double blind clinical trial, identical packets ...."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-01 10:53:19 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Bhattacharya-1998">
<DESCRIPTION>
<P>No blinding procedure described; rice-based and glucose based solutions likely to be different.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 10:39:05 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Choice-2001">
<DESCRIPTION>
<P>"Double blind."</P>
<P>"The 2 ORS preparations were similar in appearance and packaged in identical polyethylene bags."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-19 07:26:39 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Dutta-2000">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-03 11:46:15 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Faruque-1996">
<DESCRIPTION>
<P>"double blind" but method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-08 10:40:32 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Pulungsih-2006">
<DESCRIPTION>
<P>"Double blind" reduced osmolarity and standard ORS solutions identical in appearance; sachets identical in appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-08 10:40:33 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:38:08 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Alam-1999">
<DESCRIPTION>
<P>"Data collected on patients withdrawn from the study were included in the analysis up to the time of withdrawal."</P>
<P>Loss to follow-up: Reduced 13/147 (8.8%) and Higher 16/153 (10.5%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:38:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alam-2000">
<DESCRIPTION>
<P>Loss to follow up: ORS &#8804; 270 1/19 (5.3%) and ORS &#8805; 310 4/16 (25%). These percentages do not significantly differ.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:38:45 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Bhattacharya-1998">
<DESCRIPTION>
<P>Results of all eligible patients reported.</P>
<P>No loss to follow-up in both arms for both glucose and rice-based ORS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:39:06 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Choice-2001">
<DESCRIPTION>
<P>"One child was randomized for a second period of diarrhoea ..., the data from his second episode were not included in the final analysis."</P>
<P>"A total of 125 children were withdrawn from the study before cessation of diarrhoea;...Data collected on all such children up to the time of withdrawal were included in the analysis."</P>
<P>No loss to follow up reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:39:25 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Dutta-2000">
<DESCRIPTION>
<P>No loss to follow-up reported in both arms for glucose and rice-based ORS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:40:14 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Faruque-1996">
<DESCRIPTION>
<P>Results of all eligible patients reported.</P>
<P>No loss to follow-up in both arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-08 10:40:33 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Pulungsih-2006">
<DESCRIPTION>
<P>All eligible patients included in the analysis as randomized.</P>
<P>No loss to follow-up in both arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-12-01 11:06:03 +0000" MODIFIED_BY="Alfred Musekiwa" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:47:41 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1999">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:37:22 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Alam-2000">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:54:17 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Bhattacharya-1998">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:48:02 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Choice-2001">
<DESCRIPTION>
<P>Study protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:26:35 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Dutta-2000">
<DESCRIPTION>
<P>Study protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 11:00:10 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Faruque-1996">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 11:06:03 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="UNKNOWN" STUDY_ID="STD-Pulungsih-2006">
<DESCRIPTION>
<P>Protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-12-01 11:02:05 +0000" MODIFIED_BY="Alfred Musekiwa" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:47:25 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Alam-1999">
<DESCRIPTION>
<P>The study appears to be free of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:37:19 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Alam-2000">
<DESCRIPTION>
<P>The study appears to be free of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:51:00 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Bhattacharya-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:48:36 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Choice-2001">
<DESCRIPTION>
<P>The study appears to be free of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-19 07:29:38 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Dutta-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 10:57:42 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Faruque-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-01 11:02:05 +0000" MODIFIED_BY="Alfred Musekiwa" RESULT="YES" STUDY_ID="STD-Pulungsih-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-11-09 22:03:08 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-11-09 22:03:08 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-09-29 17:47:35 +0100" MODIFIED_BY="Grade Profiler">ORS &#8804; 270 mOsm/L (glucose-based) compared to ORS &#8805; 310 mOsm/L (glucose-based) for treating cholera</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>ORS </B>&#8804; <B>270 mOsm/L (glucose-based) compared to ORS </B>&#8805; <B>310 mOsm/L (glucose-based) for treating cholera</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with cholera<BR/>
<B>Settings: </B>resource-limited<BR/>
<B>Intervention:</B> ORS &#8804; 270 mOsm/L (glucose-based)<BR/>
<B>Comparison: </B>ORS &#8805; 310 mOsm/L (glucose-based)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ORS </B>&#8805; <B>310 mOsm/L (glucose-based)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ORS </B>&#8804; <B>270 mOsm/L (glucose-based)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>121<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No deaths occurred in the two trials reporting mortality</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Need for unscheduled intravenous infusion</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>285 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>245 per 1000</B>
<BR/>(188 to 319)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.66 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>616<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Symptomatic hyponatraemia</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>620<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No instances of symptomatic hyponatraemia were reported in the five trials reporting this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Biochemical hyponatraemia (serum sodium &lt; 130 mmol/L)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>121 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>202 per 1000</B>
<BR/>(132 to 310)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.67 </B>
<BR/>(1.09 to 2.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>465<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Severe biochemical hyponatraemia (serum sodium &lt; 125 mmol/L) </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(16 to 105)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.58 </B>
<BR/>(0.62 to 4.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>465<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Duration of diarrhoea (in hours)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of diarrhoea (in hours) ranged across control groups from<BR/>
<B>38 to 79 </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of diarrhoea (in hours) in the intervention groups was<BR/>
<B>2.52 lower</B>
<BR/>(6.71 lower to 1.68 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>683<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate </B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Stool output in first 24 hours after admission or randomization</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean stool output in first 24 hours after admission or randomization ranged across control groups from<BR/>
<B>-0.76 to 0.05 standard deviations</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean stool output in first 24 hours after admission or randomization in the intervention groups was<BR/>
<B>0.13 standard deviations lower</B>
<BR/>(0.43 lower to 0.17 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>581<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.13 (-0.43 to 0.17)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (eg the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Serious imprecision: wide 95% CI including both null effect (RR=1) and appreciable benefit (RR=0.75). Downgrade by 1.<BR/>
<SUP>2</SUP> Serious study limitation: all four studies had unclear reporting of allocation concealment and blinding. Downgrade by 1.<BR/>3 Serious inconsistency: statistical heterogeneity was high (I<SUP>2</SUP> = 76%, Chi<SUP>2</SUP> P = 0.0009). The reasons for this are unclear as heterogeneity persisted even after subgrouping children versus adults. Downgrade by 1.<BR/>4 Serious inconsistency: statistical heterogeneity was high (I<SUP>2</SUP> = 63%. Chi<SUP>2</SUP> P = 0.04) due to one study (Faruque 1996) showing a significant treatment effect. Heterogeneity persisted even after subgrouping children versus adults. Downgrade by 1.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-11-08 10:43:01 +0000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2011-09-29 17:47:45 +0100" MODIFIED_BY="Grade Profiler">ORS &#8804; 270 mOsm/L (rice-based) compared to ORS &#8805; 310 mOsm/L (glucose-based) for treating cholera</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>ORS </B>&#8804;<B> 270 mOsm/L (rice-based) compared to ORS </B>&#8805; <B>310 mOsm/L (glucose-based) for treating cholera</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with cholera<BR/>
<B>Settings: </B>resource-limited<BR/>
<B>Intervention:</B> ORS &#8804; 270 mOsm/L (rice-based)<BR/>
<B>Comparison: </B>ORS &#8805; 310 mOsm/L (glucose-based)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ORS </B>&#8805;<B> 310 mOsm/L (glucose-based)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ORS </B>&#8804;<B> 270 mOsm/L (rice-based) </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Need for unscheduled intravenous infusion</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Symptomatic hyponatraemia</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No instances of symptomatic hyponatraemia were reported in the one trial that assessed this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Severe biochemical </B>hyponatraemia<B> (serum sodium &lt; 125 mmol/L) </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(0 to 162)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.35 </B>
<BR/>(0.02 to 8.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>102<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Biochemical </B>hyponatraemia<B> (serum sodium &lt; 130 mmol/L)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>180 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>119 per 1000</B>
<BR/>(47 to 304)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.66 </B>
<BR/>(0.26 to 1.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>102<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Duration of </B>diarrhoea<B> (in hours)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of diarrhoea (in hours) ranged across control groups from<BR/>
<B>38 to 47 hours</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of diarrhoea (in hours) in the intervention groups was<BR/>
<B>11.42 lower</B>
<BR/>(13.8 to 9.04 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>102<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Stool output in first 24 hours after admission or randomization</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trials reported this outcome</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (eg the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Very serious imprecision: the 95% CI is wide and the two trials are small. Downgrade by 2.<BR/>
<SUP>2</SUP> Serious inconsistency: statistical heterogeneity is high (I<SUP>2</SUP> = 90%, Chi<SUP>2</SUP> P = 0.001). Downgrade by 1.<BR/>
<SUP>3</SUP> Serious imprecision: the two trials are small. Downgrade by 1.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-11-08 10:43:06 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Detailed search strategies</TITLE>
<TABLE COLS="6" ROWS="20">
<TR>
<TH>
<P>Search set</P>
</TH>
<TH>
<P>CIDG SR*</P>
</TH>
<TH>
<P>CENTRAL**</P>
</TH>
<TH>
<P>MEDLINE**</P>
</TH>
<TH>
<P>EMBASE**</P>
</TH>
<TH>
<P>LILACS**</P>
</TH>
</TR>
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>cholera</P>
</TD>
<TD>
<P>cholera</P>
</TD>
<TD>
<P>CHOLERA</P>
</TD>
<TD>
<P>CHOLERA</P>
</TD>
<TD>
<P>cholera</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>rehydration solutions</P>
</TD>
<TD>
<P>oral rehydration solution</P>
</TD>
<TD>
<P>cholera</P>
</TD>
<TD>
<P>cholera</P>
</TD>
<TD>
<P>oral rehydration</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>fluid therapy</P>
</TD>
<TD>
<P>fluid therapy</P>
</TD>
<TD>
<P>1 or 2</P>
</TD>
<TD>
<P>1 or 2</P>
</TD>
<TD>
<P>hypotonic</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>hypotonic</P>
</TD>
<TD>
<P>hypotonic solution</P>
</TD>
<TD>
<P>REHYDRATION SOLUTIONS</P>
</TD>
<TD>
<P>FLUID THERAPY</P>
</TD>
<TD>
<P>reduced osmolarity</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>ORS</P>
</TD>
<TD>
<P>ORS</P>
</TD>
<TD>
<P>FLUID THERAPY</P>
</TD>
<TD>
<P>HYPOTONIC SOLUTION</P>
</TD>
<TD>
<P>2 or 3 or 4</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>2 or 3 or 4 or 5</P>
</TD>
<TD>
<P>HYPOTONIC SOLUTIONS</P>
</TD>
<TD>
<P>ORAL REHYDRATION THERAPY</P>
</TD>
<TD>
<P>1 and 5</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>1 and 6</P>
</TD>
<TD>
<P>OSMOLAR CONCENTRATION</P>
</TD>
<TD>
<P>ORAL REHYDRATION SOLUTION</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>8</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>oral rehydration solution</P>
</TD>
<TD>
<P>oral rehydration solution</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>9</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>ORS</P>
</TD>
<TD>
<P>ORS</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>osmolar*</P>
</TD>
<TD>
<P>OSMOLARITY</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>11</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>osmolality</P>
</TD>
<TD>
<P>HYPEROSMOLARITY</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>reduced osmolarity</P>
</TD>
<TD>
<P>osmolar$</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>13</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>hypo-osmolar</P>
</TD>
<TD>
<P>osmolality</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>14</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>4-13/OR</P>
</TD>
<TD>
<P>reduced ADJ osmolarity</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>15</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>3 and 14</P>
</TD>
<TD>
<P>Hypo ADJ osmolar$</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>16</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Limit 15 to human</P>
</TD>
<TD>
<P>4-15/OR</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>17</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>3 and 16</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P>18</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>Limit 17 to human</P>
</TD>
<TD>
<P>--</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>*Cochrane Infectious Diseases Group Specialized Register</P>
</TD>
<TD>
<P>**Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Alderson 2004); Upper case: MeSH or EMTREE heading; Lower case: free text term</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-11-08 10:43:06 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Composition of oral rehydration solutions used in the trials</TITLE>
<TABLE COLS="9" ROWS="8">
<TR>
<TH>
<P>ORS type</P>
</TH>
<TH>
<P>Trials</P>
</TH>
<TH>
<P>Sodium<SUP>a</SUP>
</P>
</TH>
<TH>
<P>Potassium<SUP>a</SUP>
</P>
</TH>
<TH>
<P>Chloride<SUP>a</SUP>
</P>
</TH>
<TH>
<P>Citrate<SUP>a</SUP>
</P>
</TH>
<TH>
<P>Glucose<SUP>a</SUP>
</P>
</TH>
<TH>
<P>Rice powder<SUP>b</SUP>
</P>
</TH>
<TH>
<P>Total osmolarity<SUP>a</SUP>
</P>
</TH>
</TR>
<TR>
<TD>
<P>ORS &#8805; 310 (glucose-based)</P>
</TD>
<TD>
<P>All trials</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>111</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>311</P>
</TD>
</TR>
<TR>
<TD>
<P>ORS &#8804; 270 (glucose-based)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Dutta-2001" TYPE="STUDY">Dutta 2001</LINK>
</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>224</P>
</TD>
</TR>
<TR>
<TD>
<P>"</P>
</TD>
<TD>
<P>
<LINK REF="STD-Faruque-1996" TYPE="STUDY">Faruque 1996</LINK>
</P>
</TD>
<TD>
<P>67</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>249</P>
</TD>
</TR>
<TR>
<TD>
<P>"</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>
<BR/>
<LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>
</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>268</P>
</TD>
</TR>
<TR>
<TD>
<P>"</P>
</TD>
<TD>
<P>
<LINK REF="STD-Alam-1999" TYPE="STUDY">Alam 1999</LINK>
<BR/>
<LINK REF="STD-Choice-2001" TYPE="STUDY">Choice 2001</LINK>
<BR/>
<LINK REF="STD-Pulungsih-2006" TYPE="STUDY">Pulungsih 2006</LINK>
</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>245</P>
</TD>
</TR>
<TR>
<TD>
<P>ORS &#8804; 270 (rice-based)</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bhattacharya-1998" TYPE="STUDY">Bhattacharya 1998</LINK>
<BR/>
<LINK REF="STD-Dutta-2000" TYPE="STUDY">Dutta 2000</LINK>
</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>--</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>178</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ORS: oral rehydration solution; <SUP>a</SUP>mmol/L; <SUP>b</SUP>g</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-08 10:50:20 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-08 10:49:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Oral rehydration solution (ORS) formulations &#8804; 270 mOsm/L (glucose-based) versus ORS formulations &#8805; 310 mOsm/L (glucose-based)</NAME>
<DICH_OUTCOME CHI2="4.962365207495775" CI_END="1.1189413674286794" CI_START="0.6616123587332264" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8604100402649137" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="89" I2="19.393276537609502" I2_Q="42.002305128687055" ID="CMP-001.01" LOG_CI_END="0.048807330076764" LOG_CI_START="-0.17939639088067125" LOG_EFFECT_SIZE="-0.0652945304019536" METHOD="MH" MODIFIED="2011-05-19 13:51:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29118096761900625" P_Q="0.18915257989158085" P_Z="0.2620389774636459" Q="1.7242064572028777" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="304" TOTAL_2="312" WEIGHT="100.0" Z="1.121584936813144">
<NAME>Need for unscheduled intravenous infusion</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS &#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4518715700447986" CI_END="1.1130519202338105" CI_START="0.2903851837814234" DF="1" EFFECT_SIZE="0.568518941122775" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" I2="31.12338442103772" ID="CMP-001.01.01" LOG_CI_END="0.04651542322520602" LOG_CI_START="-0.537025546257491" LOG_EFFECT_SIZE="-0.24525506151614246" NO="1" P_CHI2="0.2282281689526543" P_Z="0.0994558694807082" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="48" WEIGHT="18.67319311448376" Z="1.6474973060552112">
<NAME>Children</NAME>
<DICH_DATA CI_END="2.1888113588790823" CI_START="0.006736486403622614" EFFECT_SIZE="0.12142857142857143" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3402083338255238" LOG_CI_START="-2.171566562425452" LOG_EFFECT_SIZE="-0.9156791142999641" ORDER="1" O_E="0.0" SE="1.4754290075440841" STUDY_ID="STD-Alam-2000" TOTAL_1="19" TOTAL_2="16" VAR="2.1768907563025213" WEIGHT="4.325260385942723"/>
<DICH_DATA CI_END="1.41300485793577" CI_START="0.35005276173685673" EFFECT_SIZE="0.7032967032967034" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.15014365496325896" LOG_CI_START="-0.4558664916376718" LOG_EFFECT_SIZE="-0.1528614183372064" ORDER="2" O_E="0.0" SE="0.3559733599119925" STUDY_ID="STD-Choice-2001" TOTAL_1="26" TOTAL_2="32" VAR="0.12671703296703296" WEIGHT="14.347932728541034"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5123426777069136" CI_END="1.2354430665108067" CI_START="0.6962092174620844" DF="2" EFFECT_SIZE="0.9274302402630867" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="72" I2="20.393025292813288" ID="CMP-001.01.02" LOG_CI_END="0.09182273640753495" LOG_CI_START="-0.15726023117178095" LOG_EFFECT_SIZE="-0.032718747382122965" NO="2" P_CHI2="0.2847422211149603" P_Z="0.6066164136663381" STUDIES="3" TAU2="0.0" TOTAL_1="259" TOTAL_2="264" WEIGHT="81.32680688551623" Z="0.5149092859414801">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.5478074590380846" CI_START="0.7665127325030856" EFFECT_SIZE="1.0892263882297104" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="43" LOG_CI_END="0.1897169352370248" LOG_CI_START="-0.11548062670666509" LOG_EFFECT_SIZE="0.03711815426517982" ORDER="3" O_E="0.0" SE="0.17927455863802014" STUDY_ID="STD-Alam-1999" TOTAL_1="147" TOTAL_2="153" VAR="0.032139367374856925" WEIGHT="48.17042491824411"/>
<DICH_DATA CI_END="1.4999953614407164" CI_START="0.15836971978318176" EFFECT_SIZE="0.48739495798319327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.17608991605313748" LOG_CI_START="-0.8003278517123245" LOG_EFFECT_SIZE="-0.3121189678295935" ORDER="4" O_E="0.0" SE="0.573552630131334" STUDY_ID="STD-Faruque-1996" TOTAL_1="34" TOTAL_2="29" VAR="0.3289626195305708" WEIGHT="8.636789786533248"/>
<DICH_DATA CI_END="1.344482256097187" CI_START="0.4347884794337897" EFFECT_SIZE="0.7645687645687645" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.12855507496398408" LOG_CI_START="-0.36172197191007444" LOG_EFFECT_SIZE="-0.11658344847304518" ORDER="5" O_E="0.0" SE="0.28799116424434473" STUDY_ID="STD-Pulungsih-2006" TOTAL_1="78" TOTAL_2="82" VAR="0.08293891068281313" WEIGHT="24.519592180738876"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3622198143128907" CI_END="2.5716427812954437" CI_START="1.0886822100815075" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6732309304698136" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.4102106419790146" LOG_CI_START="0.03690112626681631" LOG_EFFECT_SIZE="0.22355588412291544" METHOD="MH" MODIFIED="2011-11-08 10:49:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7144141865636155" P_Q="0.91230731754648" P_Z="0.018902744315948246" Q="0.012128328125200006" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="232" WEIGHT="100.0" Z="2.3474434107418958">
<NAME>Biochemical hyponatraemia (serum sodium &lt; 130 mmol/L)</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS &#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.735557024133677" CI_START="0.5264586150136901" DF="0" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.675371070621108" LOG_CI_START="-0.278635763087441" LOG_EFFECT_SIZE="0.19836765376683346" NO="1" P_CHI2="1.0" P_Z="0.4150295119122013" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="13.892806033447192" Z="0.815074784253552">
<NAME>Children</NAME>
<DICH_DATA CI_END="4.735557024133677" CI_START="0.5264586150136901" EFFECT_SIZE="1.5789473684210527" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.675371070621108" LOG_CI_START="-0.278635763087441" LOG_EFFECT_SIZE="0.19836765376683346" ORDER="6" O_E="0.0" SE="0.5603883365303906" STUDY_ID="STD-Dutta-2000" TOTAL_1="19" TOTAL_2="20" VAR="0.3140350877192982" WEIGHT="13.892806033447192"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3521845745494558" CI_END="2.691768820072676" CI_START="1.0590952432183847" DF="2" EFFECT_SIZE="1.6884429374967147" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="24" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.4300377581975465" LOG_CI_START="0.024935017467481897" LOG_EFFECT_SIZE="0.2274863878325142" MODIFIED="2010-04-22 10:15:35 +0100" MODIFIED_BY="Alfred Musekiwa" NO="2" P_CHI2="0.5086006235003069" P_Z="0.027718706577075668" STUDIES="3" TAU2="0.0" TOTAL_1="214" TOTAL_2="212" WEIGHT="86.10719396655281" Z="2.2012446833675487">
<NAME>Adults</NAME>
<DICH_DATA CI_END="3.3252979215419938" CI_START="1.0702214762057225" EFFECT_SIZE="1.8864795918367347" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" LOG_CI_END="0.5218305608829026" LOG_CI_START="0.029473661742005493" LOG_EFFECT_SIZE="0.27565211131245404" ORDER="7" O_E="0.0" SE="0.28921287976132043" STUDY_ID="STD-Alam-1999" TOTAL_1="147" TOTAL_2="153" VAR="0.08364408981983598" WEIGHT="55.8929522735107"/>
<DICH_DATA CI_END="2.8332019089933596" CI_START="0.2917004532463317" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.45227752575129987" LOG_CI_START="-0.5350628960677501" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="8" O_E="0.0" SE="0.5799686511904212" STUDY_ID="STD-Bhattacharya-1998" TOTAL_1="33" TOTAL_2="30" VAR="0.3363636363636364" WEIGHT="18.671722394576584"/>
<DICH_DATA CI_END="7.005751449829846" CI_START="0.5653755288020981" EFFECT_SIZE="1.9901960784313726" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8454547253479068" LOG_CI_START="-0.247662993045316" LOG_EFFECT_SIZE="0.2988958661512954" ORDER="9" O_E="0.0" SE="0.6421027588041529" STUDY_ID="STD-Faruque-1996" TOTAL_1="34" TOTAL_2="29" VAR="0.41229595286390414" WEIGHT="11.542519298465525"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7038865410947757" CI_END="4.041616697769788" CI_START="0.6151839035839872" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5768124609236958" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="0.0" I2_Q="1.115408176597209" ID="CMP-001.03" LOG_CI_END="0.6065551231483708" LOG_CI_START="-0.21099503646427661" LOG_EFFECT_SIZE="0.19778004334204707" METHOD="MH" MODIFIED="2011-11-08 10:49:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.42658545918459256" P_Q="0.3145966845201801" P_Z="0.34297632219285845" Q="1.01127989867814" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="233" TOTAL_2="232" WEIGHT="100.00000000000001" Z="0.9483008650988377">
<NAME>Severe biochemical hyponatraemia (serum sodium &lt; 125 mmol/L)</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS &#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9191472439343427E-32" CI_END="8.098322390550605" CI_START="0.015126589692568573" DF="0" EFFECT_SIZE="0.35000000000000003" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-001.03.01" LOG_CI_END="0.908395061843384" LOG_CI_START="-1.8202589731428325" LOG_EFFECT_SIZE="-0.45593195564972433" NO="1" P_CHI2="0.0" P_Z="0.5124790765020589" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="21.203142414439885" Z="0.6549824206489313">
<NAME>Children</NAME>
<DICH_DATA CI_END="8.098322390550605" CI_START="0.015126589692568559" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.908395061843384" LOG_CI_START="-1.820258973142833" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="11" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Dutta-2000" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="21.203142414439885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8104676060712854" CI_END="5.309800036988388" CI_START="0.6848439946586523" DF="1" EFFECT_SIZE="1.9069306930693068" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.7250781661911254" LOG_CI_START="-0.16440834817937916" LOG_EFFECT_SIZE="0.2803349090058731" MODIFIED="2010-04-22 10:31:30 +0100" MODIFIED_BY="Alfred Musekiwa" NO="2" P_CHI2="0.3679820959106397" P_Z="0.21667290974236975" STUDIES="3" TAU2="0.0" TOTAL_1="214" TOTAL_2="212" WEIGHT="78.79685758556013" Z="1.2354236211207124">
<NAME>Adults</NAME>
<DICH_DATA CI_END="4.4887282063403235" CI_START="0.4730215795029289" EFFECT_SIZE="1.457142857142857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.652123309553987" LOG_CI_START="-0.32511904605866554" LOG_EFFECT_SIZE="0.1635021317476607" ORDER="12" O_E="0.0" SE="0.5740369971145494" STUDY_ID="STD-Alam-1999" TOTAL_1="147" TOTAL_2="153" VAR="0.3295184740562892" WEIGHT="70.99518851768289"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" O_E="0.0" SE="0.0" STUDY_ID="STD-Bhattacharya-1998" TOTAL_1="33" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="111.55799208718351" CI_START="0.32270211507451385" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.047500688873826" LOG_CI_START="-0.49119818810653837" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="14" O_E="0.0" SE="1.491244287100381" STUDY_ID="STD-Faruque-1996" TOTAL_1="34" TOTAL_2="29" VAR="2.223809523809524" WEIGHT="7.801669067877239"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="20.87778991479187" CI_END="1.6788033092248282" CI_START="-6.712263598511515" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5167301446433434" ESTIMABLE="YES" I2="76.05110492822082" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-11-08 10:49:36 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="8.542761135122978E-4" P_Q="0.9944066281380118" P_Z="0.23971367877968608" Q="4.914443858782013E-5" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="18.1483161420249" TOTALS="YES" TOTAL_1="337" TOTAL_2="346" UNITS="" WEIGHT="100.0" Z="1.175702803122548">
<NAME>Duration of diarrhoea</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS &#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.597892453323938" CI_END="4.291824874674379" CI_START="-9.790259400926319" DF="1" EFFECT_SIZE="-2.7492172631259697" ESTIMABLE="YES" I2="37.417565373702175" ID="CMP-001.04.01" MODIFIED="2010-04-08 09:17:12 +0100" MODIFIED_BY="Alfred Musekiwa" NO="1" P_CHI2="0.20620218760162945" P_Z="0.4441049983178694" STUDIES="2" TAU2="14.752698335020343" TOTAL_1="45" TOTAL_2="52" WEIGHT="30.25934983938117" Z="0.7652797293279694">
<NAME>Children</NAME>
<CONT_DATA CI_END="17.85699465300432" CI_START="-9.256994653004297" EFFECT_SIZE="4.300000000000011" ESTIMABLE="YES" MEAN_1="82.9" MEAN_2="78.6" ORDER="17" SD_1="27.5" SD_2="24.5" SE="6.916961107418377" STUDY_ID="STD-Choice-2001" TOTAL_1="26" TOTAL_2="32" WEIGHT="6.943565136466233"/>
<CONT_DATA CI_END="-2.175824442194504" CI_START="-6.984175557805493" EFFECT_SIZE="-4.579999999999998" ESTIMABLE="YES" MEAN_1="33.89" MEAN_2="38.47" MODIFIED="2009-12-30 18:39:00 +0000" MODIFIED_BY="Alfred Musekiwa" ORDER="18" SD_1="3.77" SD_2="3.89" SE="1.2266427224016994" STUDY_ID="STD-Dutta-2000" TOTAL_1="19" TOTAL_2="20" WEIGHT="23.315784702914936"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.050768662500097" CI_END="3.394539476477268" CI_START="-8.826283732922336" DF="3" EFFECT_SIZE="-2.7158721282225344" ESTIMABLE="YES" I2="81.30930634487935" ID="CMP-001.04.02" MODIFIED="2009-12-17 20:33:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0011071320242602711" P_Z="0.38367883360782074" STUDIES="4" TAU2="30.379818282348843" TOTAL_1="292" TOTAL_2="294" WEIGHT="69.74065016061883" Z="0.8711379694680698">
<NAME>Adults</NAME>
<CONT_DATA CI_END="7.164409142649725" CI_START="-1.164409142649725" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="43.0" ORDER="19" SD_1="18.2" SD_2="18.6" SE="2.1247375847199503" STUDY_ID="STD-Alam-1999" TOTAL_1="147" TOTAL_2="153" WEIGHT="20.2192075981894"/>
<CONT_DATA CI_END="-4.264735625803337" CI_START="-15.135264374196655" EFFECT_SIZE="-9.699999999999996" ESTIMABLE="YES" MEAN_1="37.2" MEAN_2="46.9" ORDER="20" SD_1="9.9" SD_2="11.9" SE="2.773145025658293" STUDY_ID="STD-Bhattacharya-1998" TOTAL_1="33" TOTAL_2="30" WEIGHT="17.734068609109137"/>
<CONT_DATA CI_END="1.8527468414630093" CI_START="-16.252746841463015" EFFECT_SIZE="-7.200000000000003" ESTIMABLE="YES" MEAN_1="49.9" MEAN_2="57.1" ORDER="21" SD_1="18.7" SD_2="17.9" SE="4.618833260646586" STUDY_ID="STD-Faruque-1996" TOTAL_1="34" TOTAL_2="29" WEIGHT="11.605924616014484"/>
<CONT_DATA CI_END="5.183919729249755" CI_START="-3.183919729249755" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="44.0" MEAN_2="43.0" MODIFIED="2009-12-17 20:33:11 +0000" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="13.0" SD_2="14.0" SE="2.1346921485557795" STUDY_ID="STD-Pulungsih-2006" TOTAL_1="78" TOTAL_2="82" WEIGHT="20.18144933730581"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.164468291873291" CI_END="0.16955216190999473" CI_START="-0.43325729398711516" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.13185256603856021" ESTIMABLE="YES" I2="63.2554148935072" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2011-11-08 10:49:48 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04273219447623955" P_Q="0.514086208363639" P_Z="0.3912204459728881" Q="0.42574104004497815" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.056924757681128604" TOTALS="YES" TOTAL_1="285" TOTAL_2="296" UNITS="" WEIGHT="99.99999999999999" Z="0.8574061942016928">
<NAME>Stool output in first 24 hours after admission or randomization</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS &#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5468612222865225" CI_START="-0.4881742297619271" DF="0" EFFECT_SIZE="0.029343496262297673" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.9115125685401366" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="32" WEIGHT="18.67318623888001" Z="0.11113087139337334">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.5468612222865225" CI_START="-0.4881742297619271" EFFECT_SIZE="0.029343496262297673" ESTIMABLE="YES" MEAN_1="203.7" MEAN_2="201.0" ORDER="23" SD_1="100.6" SD_2="82.0" SE="0.2640445080146056" STUDY_ID="STD-Choice-2001" TOTAL_1="26" TOTAL_2="32" WEIGHT="18.67318623888001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.041531292351962" CI_END="0.1988994433198239" CI_START="-0.5693241810385821" DF="2" EFFECT_SIZE="-0.18521236885937908" ESTIMABLE="YES" I2="75.12911499950097" ID="CMP-001.05.02" NO="2" P_CHI2="0.01793928040316406" P_Z="0.34462710923052997" STUDIES="3" TAU2="0.08380504585420315" TOTAL_1="259" TOTAL_2="264" WEIGHT="81.32681376111998" Z="0.9450622473603413">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.2772783096924204" CI_START="-0.17552072365295018" EFFECT_SIZE="0.0508787930197351" ESTIMABLE="YES" MEAN_1="212.0" MEAN_2="207.0" ORDER="24" SD_1="97.0" SD_2="99.0" SE="0.11551208004764157" STUDY_ID="STD-Alam-1999" TOTAL_1="147" TOTAL_2="153" WEIGHT="33.654844860483806"/>
<CONT_DATA CI_END="-0.24543497343041298" CI_START="-1.2734529012170093" EFFECT_SIZE="-0.7594439373237112" ESTIMABLE="YES" MEAN_1="205.6" MEAN_2="287.5" ORDER="25" SD_1="109.0" SD_2="103.5" SE="0.26225429035825926" STUDY_ID="STD-Faruque-1996" TOTAL_1="34" TOTAL_2="29" WEIGHT="18.813149551297926"/>
<CONT_DATA CI_END="0.26990072164733026" CI_START="-0.350152008265449" EFFECT_SIZE="-0.04012564330905937" ESTIMABLE="YES" MEAN_1="3792.0" MEAN_2="3894.0" ORDER="26" SD_1="2844.0" SD_2="2190.0" SE="0.15817962340218394" STUDY_ID="STD-Pulungsih-2006" TOTAL_1="78" TOTAL_2="82" WEIGHT="28.858819349338255"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1762248795816965" CI_END="1.4031567039872088" CI_START="0.924899193069324" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1392008177962223" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="83" I2="14.982243841362017" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.14710617557332067" LOG_CI_START="-0.03390559945499996" LOG_EFFECT_SIZE="0.05660028805916035" METHOD="MH" MODIFIED="2011-05-19 13:51:46 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.27812593162121513" P_Q="1.0" P_Z="0.2203055414731212" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="182" WEIGHT="100.00000000000001" Z="1.225716129165522">
<NAME>Vomiting during rehydration</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS &#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1762248795816965" CI_END="1.4031567039872088" CI_START="0.924899193069324" DF="1" EFFECT_SIZE="1.1392008177962223" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="83" I2="14.982243841362017" ID="CMP-001.06.02" LOG_CI_END="0.14710617557332067" LOG_CI_START="-0.03390559945499996" LOG_EFFECT_SIZE="0.05660028805916035" NO="2" P_CHI2="0.27812593162121513" P_Z="0.2203055414731212" STUDIES="2" TAU2="0.0" TOTAL_1="181" TOTAL_2="182" WEIGHT="100.00000000000001" Z="1.225716129165522">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.539641791544551" CI_START="0.9406585183441534" EFFECT_SIZE="1.2034438775510203" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="64" LOG_CI_END="0.1874196909331144" LOG_CI_START="-0.026568007300090995" LOG_EFFECT_SIZE="0.0804258418165117" ORDER="27" O_E="0.0" SE="0.12569743319837456" STUDY_ID="STD-Alam-1999" TOTAL_1="147" TOTAL_2="153" VAR="0.015799844712659838" WEIGHT="75.35931158646365"/>
<DICH_DATA CI_END="1.3698900974534625" CI_START="0.6487596382722574" EFFECT_SIZE="0.9427244582043344" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.136685726292112" LOG_CI_START="-0.18791617701652952" LOG_EFFECT_SIZE="-0.025615225362208727" ORDER="29" O_E="0.0" SE="0.19067276480883164" STUDY_ID="STD-Faruque-1996" TOTAL_1="34" TOTAL_2="29" VAR="0.03635610323984402" WEIGHT="24.640688413536363"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-11-08 10:50:20 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Oral rehydration solution (ORS) formulations &#8804; 270 mOsm/L (rice-based) versus ORS formulations &#8805; 310 mOsm/L (glucose-based)</NAME>
<DICH_OUTCOME CHI2="1.1085458871343663" CI_END="1.688374917345012" CI_START="0.25610962851396846" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6575781876503609" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="9.791736038547" I2_Q="8.498564979700278" ID="CMP-002.01" LOG_CI_END="0.227468891611032" LOG_CI_START="-0.5915740938006838" LOG_EFFECT_SIZE="-0.18205260109482588" METHOD="MH" MODIFIED="2011-11-08 10:50:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29239829283491126" P_Q="0.2958346610021071" P_Z="0.3835897600429725" Q="1.0928790349333304" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="50" WEIGHT="100.00000000000001" Z="0.8713011350883659">
<NAME>Biochemical hyponatraemia (serum sodium &lt; 130 mmol/L)</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS&#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6211767112374993" CI_START="0.30598706701020695" DF="0" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.5588497186426835" LOG_CI_START="-0.5142969292203792" LOG_EFFECT_SIZE="0.02227639471115221" NO="1" P_CHI2="1.0" P_Z="0.9351477658368988" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="42.66238973536488" Z="0.08136992539872921">
<NAME>Children</NAME>
<DICH_DATA CI_END="3.6211767112374993" CI_START="0.30598706701020695" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5588497186426835" LOG_CI_START="-0.5142969292203792" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="29" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Dutta-2000" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="42.66238973536488"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7365657690083727" CI_START="0.07614534808790198" DF="0" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.23969123600642625" LOG_CI_START="-1.1183566236669515" LOG_EFFECT_SIZE="-0.43933269383026263" NO="2" P_CHI2="1.0" P_Z="0.20475910546631515" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="57.33761026463513" Z="1.2681088534617235">
<NAME>Adults</NAME>
<DICH_DATA CI_END="1.7365657690083727" CI_START="0.07614534808790198" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.23969123600642625" LOG_CI_START="-1.1183566236669515" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="30" O_E="0.0" SE="0.7977240352174656" STUDY_ID="STD-Bhattacharya-1998" TOTAL_1="33" TOTAL_2="30" VAR="0.6363636363636364" WEIGHT="57.33761026463513"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9191472439343427E-32" CI_END="8.098322390550605" CI_START="0.015126589692568573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35000000000000003" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.908395061843384" LOG_CI_START="-1.8202589731428325" LOG_EFFECT_SIZE="-0.45593195564972433" METHOD="MH" MODIFIED="2011-11-08 10:50:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.5124790765020589" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="50" WEIGHT="99.99999999999999" Z="0.6549824206489313">
<NAME>Severe biochemical hyponatraemia (serum sodium &lt; 125 mmol/L)</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS&#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9191472439343427E-32" CI_END="8.098322390550605" CI_START="0.015126589692568573" DF="0" EFFECT_SIZE="0.35000000000000003" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" ID="CMP-002.02.01" LOG_CI_END="0.908395061843384" LOG_CI_START="-1.8202589731428325" LOG_EFFECT_SIZE="-0.45593195564972433" NO="1" P_CHI2="0.0" P_Z="0.5124790765020589" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.6549824206489313">
<NAME>Children</NAME>
<DICH_DATA CI_END="8.098322390550605" CI_START="0.015126589692568559" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.908395061843384" LOG_CI_START="-1.820258973142833" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="31" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Dutta-2000" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="32" O_E="0.0" SE="0.0" STUDY_ID="STD-Bhattacharya-1998" TOTAL_1="33" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="10.231970259271554" CI_END="-9.040959049163579" CI_START="-13.797338562939036" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.419148806051307" ESTIMABLE="YES" I2="90.22671123292345" I2_Q="90.22671123292345" ID="CMP-002.03" MODIFIED="2011-11-08 10:50:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0013802841940723232" P_Q="0.0013802841940723232" P_Z="4.914848350424358E-21" Q="10.231970259271554" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="9.410990157174709">
<NAME>Duration of diarrhoea</NAME>
<GROUP_LABEL_1>ORS&#8804; 270 mOsm/L</GROUP_LABEL_1>
<GROUP_LABEL_2>ORS&#8805; 310 mOsm/L</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ORS&#8804; 270 mOsm/L</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ORS&#8805; 310 mOsm/L</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.368994455183081" CI_START="-11.891005544816917" DF="0" EFFECT_SIZE="-9.129999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2009-12-30 18:47:13 +0000" MODIFIED_BY="Alfred Musekiwa" NO="1" P_CHI2="1.0" P_Z="9.103046919032208E-11" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="74.19223443008671" Z="6.4811427896054">
<NAME>Children</NAME>
<CONT_DATA CI_END="-6.368994455183081" CI_START="-11.891005544816917" EFFECT_SIZE="-9.129999999999999" ESTIMABLE="YES" MEAN_1="29.34" MEAN_2="38.47" MODIFIED="2009-12-30 18:47:13 +0000" MODIFIED_BY="Alfred Musekiwa" ORDER="33" SD_1="4.83" SD_2="3.89" SE="1.4087021836091769" STUDY_ID="STD-Dutta-2000" TOTAL_1="19" TOTAL_2="20" WEIGHT="74.19223443008671"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-13.31864795804804" CI_START="-22.68135204195196" DF="0" EFFECT_SIZE="-18.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" NO="2" P_CHI2="1.0" P_Z="4.840651946881014E-14" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="25.807765569913283" Z="7.536145841108485">
<NAME>Adults</NAME>
<CONT_DATA CI_END="-13.31864795804804" CI_START="-22.68135204195196" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="28.9" MEAN_2="46.9" ORDER="34" SD_1="5.7" SD_2="11.9" SE="2.388488808405597" STUDY_ID="STD-Bhattacharya-1998" TOTAL_1="33" TOTAL_2="30" WEIGHT="25.807765569913283"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-11-08 10:40:34 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-11-08 10:40:34 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-11-08 10:40:34 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATMAAAHsCAIAAAAxUt3zAAAVrElEQVR42u3dsY4lxRXG8ZFICDYg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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS>
<EXTENSION ID="AFF_8B0BF7C782E26AA20026894812FC1FDD_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="8B0BF7C782E26AA20026894812FC1FDD">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>South African Cochrane Centre, Medical Research Council of South Africa</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_6985_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="6985">
<ADDRESS>
<DEPARTMENT>South African Cochrane Centre</DEPARTMENT>
<ORGANISATION>Medical Research Council of South Africa</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>